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Professor Lee Ratner, Chairperson 
 
 
 
Retroviruses have evolved complex mechanisms to regulate their cellular tropism 
and gene expression.  It is generally accepted that productive infections proceed via 
interactions between viral envelope molecules and specific receptors on the host cell 
surface.  Currently, there is no known receptor for HTLV-1, though a number of factors 
that enhance entry have been identified.  In an effort to identify a cellular receptor or 
attachment factor for HTLV-1, we carried out a retroviral cDNA library screen, in which 
cDNA from permissive HeLa S3 cells was introduced into poorly susceptible NIH 3T3 
cells.  These cells were selected after infection with HTLV-1 envelope pseudotyped viral 
particles expressing a drug resistance gene.  We isolated approximately 460 cDNAs, of 
which 20 were prioritized as potential candidates.  These candidates are being tested to 
determine if they participate in viral entry. 
In addition to encoding the structural and enzymatic genes common to all 
retroviruses, HTLV-1 also encodes several accessory genes which contribute to viral 
replication and the maintenance of gene expression.  A newly identified viral gene, 
HTLV-1 bZIP factor or hbz, has been shown to have pleiotropic effects as it functions 
 iii 
differently in its protein and mRNA forms.  In an effort to elucidate its role in HTLV-1 
replication, we identified a novel function.  Mutations that abrogated the hbz mRNA or 
disrupted a stem-loop in hbz mRNA, or mutations that eliminated or truncated the HBZ 
protein were introduced in a functional molecular clone of HTLV-1.  The protein and 
stem-loop mutants had no effect on viral gene expression.  However, the mutant that 
disrupted hbz mRNA expressed lower levels of tax mRNA, suggesting that hbz promotes 
tax expression.  We found that this effect of hbz was indirect, as hbz represses another 
accessory gene, p30II, which is known to sequester tax mRNA in the nucleus.  These 
results provide new insights into the regulation of HTLV-1 infection, specifically viral 
entry and gene expression. 
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HTLV-1 AND DISEASE 
 
HTLV-1 belongs to the Deltaretrovirus genus of the Orthoretroviridae family, 
which also includes the three other types of the human T-cell leukemia viruses – type 2 
(HTLV-2), type 3 (HTLV-3), and type 4 (HTLV-4), the three types of the simian T-cell 
leukemia viruses – type 1 (STLV-1), type 2 (STLV-2), and type 3 (STLV-3), and the 
bovine leukemia virus (BLV).  The HTLVs and STLVs are collectively known as primate 
T-cell leukemia viruses, or PTLVs.   HTLV-1 and -2 were discovered in the early-80s 
(Gallo, 2005; Kalyanaraman et al., 1982; Poiesz et al., 1980), while HTLV-3 and -4 were 
discovered in 2005 (Calattini et al., 2005; Mahieux and Gessain, 2009; Wolfe et al., 
2005).  Of the four HTLVs, HTLV-1 is the only one known to cause disease.  It was the 
first human retrovirus discovered, isolated from a cell-line derived from a patient with 
cutaneous T-cell lymphoma (Poiesz et al., 1980).  It is the etiological agent of adult T-cell 
leukemia/lymphoma (ATLL), and a variety of inflammatory disorders, including HTLV-
associated myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-associated 
uveitis, and infective dermatitis (Proietti et al., 2005).  Although the exact number of 
sero-positive individuals is unknown, an estimated 15-20 million people are infected with 
HTLV worldwide (de The and Kazanji, 1996).  HTLV-1 is endemic to the Caribbean, 
southern Japan, parts of Africa and South America, and Melanesia; it is also present in 
Europe and North America.  Most HTLV-1-infected individuals never develop any major 
clinical manifestation; only about 2-6% develop disease after a long latency period, 
usually several decades. 
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ORIGINS OF HTLV-1 
 
HTLV-infection is present worldwide, but Africa is the only continent where all 
seven forms of PTLV exist.  Based on this, and phylogenetic studies, the common 
ancestor of all PTLV is assumed to have originated in Africa (Vandamme, Salemi, and 
Desmyter, 1998).  Based on several analytical methods, three different clades of HTLV-1 
exist (Koralnik et al., 1994).  The cosmopolitan strain (clade 1) has been transmitted to 
many populations worldwide, and it represents a very homogeneous group of viruses that 
probably originated in South Africa (Gallo, Sliski, and Wong-Staal, 1983; Gessain, Gallo, 
and Franchini, 1992; Koralnik et al., 1994).  The second clade (clade 2; HTLVZaire) was 
identified in central Africa, and has also been exported to other countries.  The third clade 
(clade 3; HTLVMel) was identified in remote inhabitants of Papua New Guinea and the 
Solomon Islands, and in Aborigines from Australia (Franchini, 1995).  Evidence indicates 
that HTLVMel and the cosmopolitan HTLV-1 probably derived from a common ancestor, 
but evolved independently.  Evolutionary analysis suggests that HTLVMel is the most 
divergent clade, preceding the split between the HTLVZaire and HLTV-1 cosmopolitan 
groups. 
Similar analyses have been carried out on STLV-1 strains of African and Asian 
origin.  STLV, from a single species, was sorted into genetically distinct clades.  This 
suggests recent interspecies transfer between human and primates.  In fact, the human 
clade 2 and the common chimpanzee clade S5 cluster together, suggesting that HTLVZaire 
may have resulted from a cross-species transmission of chimpanzee STLV to human. 
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HTLV-1 GENOME 
 
The HTLV-1 genome is 9 kb in length (Fig.1) and represents a typical replication 
competent complex retrovirus.  The viral open reading frames (ORFs) are flanked by two 
long terminal repeats, the 5′ and 3′ LTRs, which contain the viral promoter and 
polyadenylation sequences, respectively.  One unique feature of the HTLV-1 genome is 
that it also initiates transcription from the 3′ LTR (Gaudray et al., 2002; Larocca et al., 
1989).   
The gag gene is transcribed and translated as a precursor to the internal structural 
proteins.  It is proteolytically processed into the mature structural proteins capsid (CA), 
matrix (MA), and nucleocapsid (NC).  The pol gene encodes the enzymes reverse 
transcriptase (RT), which has DNA polymerase and RNase H activities, and integrase 
(IN), which mediates replication of the genome.  The pro gene encodes the viral protease 
(PR), which acts late in assembly and proteolytically processes the proteins encoded by 
gag, pro, and pol.  The env gene is a precursor to envelope glycoproteins; it encodes the 
surface (SU) and transmembrane (TM) glycoproteins. 
Another unique aspect of the HTLV-1 genome is its pX region, located between 
the env gene and the 3′ LTR.  It consists of four alternatively spliced ORFs (I to IV) on 
the sense strand, and two alternatively spliced ORFs on the antisense strand, which 
encode regulatory and accessory proteins.  ORFs III and IV are translated from the same 
doubly spliced transcript, and encode the Rex and Tax proteins, respectively.  Rex is 
involved in the nuclear export of unspliced or singly spliced viral RNA (Heger et al., 
1999; Hidaka et al., 1988), while Tax transactivates the 5′ LTR and up-regulates  
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Fig. 1.  Schematic representation of the HTLV-1 genome.  The viral mRNAs, their 
direction of transcription, and location of the open reading frames (black boxes) are 
shown.  The dotted lines represent the introns.    
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transcription of many cellular genes involved in host cell proliferation (Giebler et al., 
1997; Pise-Masison et al., 2001; Yin and Gaynor, 1996).  ORF III also encodes a singly 
spliced truncated form of Rex, p21Rex, which is less well characterized.  ORFs I and II 
produce alternatively spliced mRNA, which encode four accessory genes – p12I, p27I, 
p13II, and p30II (Berneman et al., 1992; Ciminale et al., 1996; Furukawa and Shiku, 1991; 
Koralnik et al., 1992).  The antisense strand transcribes the HTLV-1 bZIP factor, hbz 
(Gaudray et al., 2002).  Three alternatively spliced isoforms of hbz exist – hbz SP1 and 
hbz SP2 are spliced, while hbz US is unspliced (Cavanagh et al., 2006; Murata et al., 
2006; Satou et al., 2006).  hbz SP1 and hbz US encode proteins that are >95% identical, 
differing only in the first seven amino acids.  These accessory genes are critical for viral 
infectivity, maintenance of high viral loads, regulation of viral transcription, and viral 
pathogenesis (Albrecht et al., 2000; Albrecht and Lairmore, 2002; Bartoe et al., 2000; 
Ciminale et al., 1999; Collins et al., 1998; Lairmore et al., 2000; Matsuoka and Green, 
2009; Nicot et al., 2004; Nicot et al., 2001; Satou and Matsuoka, 2007; Zhang et al., 
2001; Zhang et al., 2000).      
 
HTLV-1 REPLICATION CYCLE 
 
The HTLV-1 replication cycle (Fig. 2) potentially begins with the binding of the 
viral envelope (Env) to the host cell receptor(s)/attachment factor(s), which has not been 
conclusively identified yet.  This interaction is thought to trigger a conformational change 
in Env, which subsequently mediates its fusion to the host cell plasma membrane.  Fusion 
leads to the release of the viral core into the cytoplasm, where its RNA genome is reverse  
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Fig. 2. HTLV-1 replication cycle.  After binding to the host cell receptor, which is still 
unidentified (1), the viral membrane fuses with the plasma membrane (2), and the viral 
core is released into the cytoplasm, where it is uncoated (3).  The viral RNA genome is 
reverse transcribed (4), and the viral DNA is integrated into the host genome (5), forming 
the provirus.  The viral genome is transcribed (6) and the unspliced and spliced 
transcripts are translocated to the cytoplasm (7).  Translation of the various transcripts (8) 
produces the Gag, Gag-Pro, and Gag-Pro-Pol precursor proteins, the Env protein, and 
accessory proteins.  The Gag precursor proteins, Env protein, and viral genome assemble 
at the plasma membrane (9).  Budding occurs, and immature viral particles are released 
(10).  Viral maturation occurs during budding, when the Gag precursors are processed by 
the viral protease (11).  See text for more details. 
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transcribed to DNA by the viral reverse transcriptase.  The DNA copy of the viral 
genome is then integrated into the host DNA by the viral integrase, forming the provirus, 
which is the template for transcription of the viral genome.  By integrating into the 
genome of the host cell, the virus is able to take advantage of the host cell machinery to 
replicate its genome.  A number of different transcripts are generated from the provirus, 
including an unspliced, full-length copy of the viral genome, which (i) serves to encode 
the viral Gag, Gag-Pro, and Gag-Pro-Pol precursors, and (ii) is encapsidated as the viral 
genome in progeny particles.  Singly spliced transcripts, encoding the Env precursor, and 
doubly spliced transcripts, encoding the regulatory and accessory proteins, are also 
generated.  The doubly spliced transcripts are readily exported out of the nucleus, while 
the unspliced and singly spliced transcripts require Rex to bind to their Rex response 
elements, RxRE, to promote their export.  Once in the cytoplasm, these transcripts are 
translated into their precursor forms, or regulatory/accessory proteins.  The Gag, Gag-
Pro, Gag-Pro-Pol, and Env proteins then come together at a common site at the cell 
membrane, and assemble into viral particles.  Upon budding from the plasma membrane, 
these particles are considered immature, as they have not been processed yet.  Maturation 
of the virion occurs through the activation of the viral protease and cleavage of the Gag, 
Gag-Pro, and Gag-Pro-Pol precursors. 
 
HTLV-1 ENTRY 
 
The HTLV-1 envelope protein is synthesized as a 62-kDa precursor glycoprotein, 
that is cleaved and glycosylated in the endoplasmic reticulum and Golgi (Paine, Gu, and 
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Ratner, 1994; Pique, Tursz, and Dokhelar, 1990).  It is expressed on the surface of 
infected cells; during the budding process, the viral particles at the cell surface egress and 
are coated with an envelope that consists of a plasma-membrane derived lipid bilayer and 
envelope glycoproteins (Env).  Env is composed of a 46-kDa surface amino terminal 
protein, gp46 (SU), and a 21-kDa transmembrane carboxy terminal component, gp21 
(TM).  SU is entirely extracellular and has four N-glycosylation sites (Delamarre et al., 
1996); TM is membrane-anchored, has one N-glycosylation site, and like all retroviral 
TM, has an amino terminal fusion peptide. 
Productive retroviral infections, leading to the formation of viral progeny, depend 
on interactions between Env and specific cellular receptors present on the cell surface.  
Analogous to other non-lentiviral retroviruses, it is assumed that an amino terminal 
receptor binding domain (RBD) in the SU binds to a cell surface receptor, leading to 
conformational changes and activation of the TM fusion peptide, which initiates 
membrane fusion (Manel et al., 2005; Weiss et al., 1985). 
Although HTLV-1 was discovered 30 years ago, its receptor is still unknown; 
evidence suggests that the PTLVs have a common receptor (Clapham, Nagy, and Weiss, 
1984; Sommerfelt and Weiss, 1990), which is widely expressed (Jassal, Pohler, and 
Brighty, 2001; Trejo and Ratner, 2000).  However, attempts to discover the receptor have 
been hindered by several factors: (1) the broad in vitro tropism has prevented studies 
from pinpointing a specific factor; (2) Env is highly fusogenic and toxic, leading to a 
rampant syncytial effect, which makes it challenging to use as a tool in fusion studies; 
and (3) it is difficult to produce high titers of cell-free virions to use in binding studies.  
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Despite the difficulties, a host of proteins have been proposed as the receptor for HTLV-1 
or an adhesion molecule that promotes infection.   
Early reports, based on human-mouse somatic cell hybrids, suggested that the 
HTLV-1 receptor was encoded on chromosome 17 (Gavalchin et al., 1995; Sommerfelt et 
al., 1988).  However, this was based on the assumption that mouse cells were resistant to 
HTLV-1; in fact, mouse cells have been shown to be susceptible, albeit poorly, to HTLV-
1 (Denesvre et al., 1995; Jassal, Pohler, and Brighty, 2001; Trejo and Ratner, 2000).  
Before 2003, other factors that had been proposed as the HTLV-1 receptor, or to be 
involved in viral entry, included the tetraspanins C33 and CD82 (Imai et al., 1992; Pique 
et al., 2000a), which interact with membrane components; vascular cell adhesion 
molecule-1 (VCAM-1) (Hildreth, Subramanium, and Hampton, 1997), which mediates 
HTLV-1-induced syncytium formation, which can be blocked by anti-gp46 antibodies; 
intercellular adhesion molecules (ICAMs) (Al-Fahim et al., 1999; Daenke and Booth, 
2000; Daenke, McCracken, and Booth, 1999; Uchiyama, Ishikawa, and Imura, 1996); 
glycophosphatidylinositol (GPI)-linked proteins (Niyogi and Hildreth, 2001) and class II 
histocompatibility (MHC II) molecules (Hildreth, 1998), probably due to their association 
with the cholesterol in lipid rafts, which has been shown to be important post-binding 
(Wielgosz et al., 2005); and the heat shock cognate protein HSC70 and 
phosphatidylglycerol (Sagara et al., 2001; Sagara et al., 1998), which participate in 
syncytium formation.  
In 2003, heparan sulfate proteoglycans (HSPGs) were shown to influence HTLV-
1 Env-mediated binding and viral entry (Okuma et al., 2003; Pinon et al., 2003).  HSPGs 
are a type of glycosaminoglycan consisting of a core protein with heparan sulfate 
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polysaccharide chains and have been implicated in the binding and receptor-mediated 
entry of numerous viruses, including a number of herpes simplex viruses, flaviviruses, 
picornaviruses, and HIV (Bobardt et al., 2003; Spillmann, 2001).  At around the same 
time, glucose transporter 1 (GLUT-1) was identified as the receptor of HTLV, based on 
the observation that cells transfected with HTLV-1 or -2 Env blocked acidification of the 
media by altering lactate production and glucose transport (Manel et al., 2003).  
However, the role of GLUT-1 as the receptor has been questioned since then, as one 
study showed evidence that activated CD4+ T cells that were susceptible to HTLV-1 
infection, expressed undetectable levels of surface GLUT-1 (Takenouchi et al., 2007).  
However, they did suggest that GLUT-1 may be required in conjunction with other 
factors, as it did enhance HTLV-1 cell-to-cell transmission.  In 2005, HSPGs were 
implicated once again, as a study showed that they mediated HTLV-1 attachment and 
entry into CD4+ T cells (Jones et al., 2005).  Another protein that has been shown to 
influence HTLV-1 entry is the coreceptor for certain isoforms of vascular endothelial 
growth factor (VEGF), neuropilin-1 (NRP-1).  Evidence suggests that HTLV-1 uses 
HSPGs and NRP-1 for entry (Lambert et al., 2009) and GLUT-1 and NRP-1, either 
individually or collectively, to infect a variety of cell types (Ghez et al., 2006).  The most 
recent study analyzed these three factors, GLUT-1, NRP-1, and HSPGs, and suggested 
that a fourth molecule, DC-specific intercellular adhesion molecule-3 (ICAM-3)-
grabbing nonintegrin (DC-SIGN), plays a critical role in HTLV-1 binding, transmission, 
and infection (Jain et al., 2009). 
Taken together, it is evident that these factors enhance entry and/or cell-to-cell 
transmission of HTLV-1, but are not the receptor for HTLV-1.  It is possible that they 
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work cooperatively, and that they may even form a complex, as evidenced by Ghez et al. 
(2006).  Chapter 2 summarizes our efforts to identify the HTLV-1 receptor/attachment 
factor using an unbiased functional cDNA library screen. 
 
HTLV-1 TRANSMISSION 
 
HTLV-1 is transmitted by three routes: vertical – from mother to child, 
predominantly through breastfeeding, horizontal – via sexual intercourse, and parenteral 
– via infected blood transfusions or the sharing of needles and syringes (Manns, Hisada, 
and La Grenade, 1999).  Interestingly, physiological transmission requires live HTLV-1-
infected cells, since fresh frozen plasma from sero-positive donors does not transmit 
HTLV-1 (Okochi, Sato, and Hinuma, 1984). 
In vitro experiments have shown that transmission by cell-free virions is very 
inefficient; in fact, free virus is not detected in the serum of infected patients (Asquith 
and Bangham, 2008).  Efficient transmission relies on direct contact between HTLV-1-
infected and uninfected cells, polarization of the microtubule-organizing center (MTOC), 
which is triggered by the viral Tax protein, and formation of the virological synapse, 
which allows the spread of viral proteins and genomic RNA into the target T lymphocyte 
(Igakura et al., 2003; Majorovits et al., 2008).  Like HIV, HTLV-1 can also efficiently 
infect dendritic cells, which can subsequently transmit the virus to CD4+ T-cells (Jones et 
al., 2008).  To facilitate its transmission, HTLV-1 takes advantage of the pleiotropic 
functions of its proteins, especially Tax, to clonally expand the population of infected 
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cells (Gatza, Watt, and Marriott, 2003; Jeang et al., 2004; Matsuoka and Jeang, 2005; 
Yoshida, 2001). 
 
HTLV-1 REGULATORY GENES 
 
As the work conducted for this dissertation involves Tax, HBZ, and p30II, the 
following sections will focus on those three factors, and not discuss the other regulatory 
genes – Rex, p12I, p27I, and p13II.  Rex is a RNA-binding post-transcriptional regulator 
that binds specifically to the Rex response element (RxRE), located at the 3′ end of sense 
viral mRNAs.  It promotes the nuclear export of unspliced and singly-spliced viral 
mRNAs and inhibits the splicing and export of doubly spliced mRNAs (Boxus and 
Willems, 2009; Kashanchi and Brady, 2005).  The pX ORF I mRNA encodes two 
accessory proteins – the 152-amino-acid p27I and the 99-amino-acid p12I.  Translation of 
p12I is initiated at an internal methionine codon in the p27I ORF.  The p27I protein is not 
very well studied, although evidence suggests that it is produced during the course of 
natural infection in vivo (Ciminale et al., 1996; Pique et al., 2000b).  The p12I protein is 
involved in a number of processes, which suggest that it is likely to promote T-cell 
proliferation and viral escape from immune surveillance (Fukumoto et al., 2009; Nicot et 
al., 2005; Nicot et al., 2001).  The pX ORF II mRNA encodes the two accessory proteins 
p30II and p13II.  Translation of p13II is initiated at an internal methionine codon in the 
p30II ORF.  The p13II protein localizes to the mitochondria and alters membrane 
potential, which causes an increase in the production of reactive oxygen species (ROS) 
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(Silic-Benussi et al., 2010).  Additionally, it binds to farnesyl pyrophosphate synthase 
(FPPS), an enzyme required for the prenylation of Ras (Lefebvre et al., 2002).   
 
TAX 
 
Tax was initially discovered as a trans-activator of HTLV-1 gene expression 
(Felber et al., 1985).  It activates the 5′ LTR by interacting with three imperfect 21-bp 
repeats, called Tax responsive elements (TxRE), in the U3 region of the LTR (Brady et 
al., 1987).  Each repeat contains an imperfect cyclic AMP response element (CRE) that is 
recognized by members of the CRE-binding protein/activating transcription factor 
(CREB/ATF) family.  Tax cooperates with CREB-2 to enhance transcription of the 
HTLV-1 promoter (Gachon et al., 2000; Reddy et al., 1997).   
Tax is also a major player in mediating viral persistence and disease development.  
The ultimate goal of HTLV-1 infection is the emergence of ATLL, and the virus uses Tax 
to this end.  The ability of Tax to immortalize cells, and produce tumors in transgenic 
mouse models (Yoshida, 2001) (Boxus et al., 2008) supports this oncogenic potential.  
Tax is actively involved in numerous cellular functions (Fig. 3) – it activates cell 
signaling pathways, reprograms the cell cycle, interferes with checkpoint control and 
inhibits DNA repair – which helps it exert its functions (Boxus and Willems, 2009; 
Matsuoka and Jeang, 2007).  Of the pathways activated by Tax, its roles in activating the 
CREB/ATF, nuclear factor-κB (NF-κB), and serum response factor (SRF) pathways 
(Azran, Schavinsky-Khrapunsky, and Aboud, 2004) are thought to be the most critical.  
Additionally, Tax has the ability to repress the function of p53  
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Fig. 3.  Cellular activities modulated by Tax.  The numerous cellular processes that 
Tax is involved in are diagrammed here.  Tax stimulates survival factors, cell-cycle 
activators, growth receptors and proliferative factors, and transcription factors, and 
inhibits cell-cycle inhibitors, DNA repair factors, and the DNA damage response.  The 
cumulative effect of the alterations of these processes is what eventually leads to the 
emergence of ATLL (Matsuoka and Jeang, 2007).  
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(Akagi et al., 1997; Gartenhaus and Wang, 1995; Reid et al., 1993; Yamato et al., 1993), 
stimulate transition of G1/S (Marriott and Semmes, 2005), interact with and degrade Rb, 
and modulate expression of cyclin-dependent kinase inhibitors (Grassmann, Aboud, and 
Jeang, 2005) all of which cooperate to ultimately lead to cellular transformation. 
  Due to its abilities in hijacking cellular functions to its advantage, Tax elicits a 
strong cytotoxic T-lymphocyte (CTL) response from the host immune surveillance 
machinery.  However, to counteract this active immune response, Tax expression is 
diminished in transformed cells, as evidenced by the fact that there is no Tax expression 
in 60% of ATLL cases (Takeda et al., 2004).  Three mechanisms for this decrease in 
expression have been described: (1) deletion of the viral promoter in the 5′ LTR 
(Miyazaki et al., 2007; Tamiya et al., 1996); (2) DNA methylation of the 5′ LTR, which 
leads to inactivation of the promoter (Koiwa et al., 2002; Taniguchi et al., 2005); and (3) 
genetic mutations (nonsense mutations, deletions, and insertions) of the tax gene 
(Furukawa et al., 2001; Takeda et al., 2004).  Analyses of the ATLL cells showed that the 
3′ LTR remains intact and is not methylated.  In addition, the pX region of HTLV-1 is 
also maintained (Matsuoka and Green, 2009).  Interestingly, hbz is expressed from the 3′ 
LTR.  Consequently, detailed analyses uncovered that all ATLL patients express the hbz 
gene, irrespective of their Tax expression levels, implicating a role for hbz in the 
development of ATLL.   
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HBZ 
 
Transcription from the minus strand of the HTLV-1 genome was first reported in 
1989 (Larocca et al., 1989).  The authors discovered a functional promoter on the anti-
sense strand and showed that minus strand RNA is transcribed in HTLV-1-infected T-
cells.  However, it was not until 2002 that a gene product encoded by the minus strand 
was characterized (Gaudray et al., 2002).  The authors identified this viral protein as a 
binding partner to CREB-2, through a yeast two-hybrid screen.  As the proteins 
associated through their respective basic leucine zipper (bZIP) domains, the authors 
designated it the HTLV-1 bZIP factor, or HBZ.  Using 5′ and 3′ rapid amplification of 
cDNA ends (RACE), they identified three hbz transcripts, generated by alternative 
splicing, of which two are spliced (hbz SP1 and SP2) and one is unspliced (hbz US) 
(Cavanagh et al., 2006; Murata et al., 2006; Satou et al., 2006).  Due to the low levels of 
expression of hbz SP2, studies have focused on hbz SP1 and hbz US.  The promoter 
regions of hbz SP1 and hbz US have been identified and both promoters are TATA-less 
(Yoshida et al., 2008). hbz SP1 has multiple transcriptional initiation sites in the R region 
of the 3′ LTR (Cavanagh et al., 2006; Yoshida et al., 2008), whereas hbz US has one 
initiation site, in the intronic region of hbz SP1 (Yoshida et al., 2008).  The transcription 
factor Sp1 has been shown to be critical for expression of hbz SP1 (Yoshida et al., 2008), 
and the TRE motif in the 3′ LTR has been shown to enhance transcription of the hbz 
transcripts (Landry et al., 2009; Yoshida et al., 2008).  However, the enhancing activity 
of the TRE motif in the 5′ LTR is much stronger than that seen in the 3′ LTR.   
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The HBZ SP1 and HBZ US proteins are 206 and 209 amino-acids long, 
respectively.  They share >95% amino acid sequence identity, and differ only at their N-
termini.  Both HBZ SP1 and HBZ US have been shown to down-regulate Tax-mediated 
LTR transcription (Arnold et al., 2006; Gaudray et al., 2002) by interacting with CREB-
2, via its bZIP domain, thus preventing it from binding to the viral CRE.  HBZ US has 
been shown to interact with other proteins, including the transcription factors JunB, c-
Jun, and JunD, through its bZIP domain.  It dimerizes with JunB and c-Jun, decreasing 
their DNA-binding activity and impairing the stability of c-Jun (Basbous et al., 2003; 
Matsumoto et al., 2005).  In contrast, the interaction between HBZ US and JunD leads to 
activation of JunD-dependent transcription (Thebault et al., 2004).  Interestingly, HBZ 
SP1 has also been shown to associate with JunD, and activate human telomerase reverse 
transcriptase (hTERT) (Kuhlmann et al., 2007).  Since activation of telomerase is 
important in the development and progression of ATLL (Uchida et al., 1999), this 
suggests that HBZ may contribute to the development and maintenance of the leukemic 
process.  HBZ SP1 and HBZ US suppress the classical NF-κB pathway by interacting 
with p65 and inducing its degradation (Zhao et al., 2009).  In addition to its bZIP domain, 
HBZ contains an N-terminal activation domain, two basic regions, and a DNA-binding 
domain.  The central regions have been shown to contain three distinct nuclear 
localization signals, at least two of which are needed for nuclear localization (Hivin et al., 
2005).  HBZ US accumulates in nuclear speckles, and was found to localize to 
heterochromatin (Hivin et al., 2005), whereas HBZ SP1 was found to localize to nucleoli 
(Murata et al., 2006).   
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A number of studies, carried out with more physiologically relevant methods, 
revealed an interesting dual functionality of HBZ SP1.  In one study, the authors 
generated HTLV-1 HBZ SP1 mutants in the context of a molecular clone and evaluated 
them for viral gene expression, protein production, and immortalization capacity.  In 
vitro, the biological properties of the HBZ SP1 mutants were indistinguishable from 
wild-type HTLV-1.  On the other hand, rabbits inoculated with these mutants became 
persistently infected.  However, compared to wild-type infected rabbits, the mutants 
exhibited reduced proviral copy numbers and a decreased antibody response to viral gene 
products.  These data suggest that HBZ SP1 is dispensable for viral replication and 
cellular immortalization in vitro, but enhances infectivity and persistence of HTLV-1 in 
vivo (Arnold et al., 2006).  In another study, the authors used short interfering RNAs 
(siRNAs) to suppress hbz transcription, and found that this inhibited proliferation of 
ATLL cells.  In addition, T-cell lines transfected with mutated hbz genes indicated that 
hbz promotes T-cell proliferation in its RNA form (Satou et al., 2006).  The authors also 
defined a stem-loop structure in the first 210bp of hbz RNA, and showed that it was 
essential for the growth promoting activity of hbz.  Furthermore, they generated hbz 
transgenic mice under the control of the CD4 promoter, and found that the percentage of 
CD4+ T-cells was elevated in splenocytes.  These data indicate that hbz plays a critical 
role in HTLV-1-mediated oncogenesis, even in the absence of tax.  Furthermore, it 
establishes a bimodal function for hbz (Fig. 4). 
All tested ATLL and HTLV-1-infected cell-lines, infected cells freshly isolated 
from ATLL patients, and peripheral blood mononuclear cells (PMBCs) isolated from 
asymptomatic HTLV-1 carriers express hbz transcripts, with hbz SP1 being the most 
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Fig. 4.  Functions of HBZ.  The various processes that HBZ is involved in are depicted 
here.  The boxes represent where the genes are located in the HTLV-1 genome, while the 
circles represent the corresponding proteins.  The arrows on the LTRs depict the direction 
of transcription.  The Tax protein up-regulates viral transcription from the 5′ LTR.  The 
HBZ protein has been shown to inhibit this process, and down-regulate Tax-mediated 
viral transcription.  Furthermore, it can influence host gene expression and enhance viral 
infectivity and persistence in vivo.  The hbz RNA has been shown to promote T-cell 
proliferation (Matsuoka and Green, 2009).  In work conducted for this dissertation 
(Chapter 3), a novel function of hbz was discovered.  The hbz RNA was shown to 
promote tax expression (red arrow).  See text for more details.   
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abundant transcript (Satou et al., 2006; Usui et al., 2008).  However, prior to this finding, 
HTLV-1 viral genes were virtually undetectable in ATLL patients.  Due to this finding, 
and the fact that the 3′ LTR is present and unmodified in ATLL and HTLV-1-infected 
cells, hbz is considered indispensable for the development of ATLL.  Furthermore, a 
recent study reported a correlation between the levels of hbz transcript and the severity of 
HAM/TSP, suggesting that expression of hbz contributes to the pathogenesis of 
HAM/TSP (Saito et al., 2009).  Taken together, it is likely that the hbz gene is an 
important player in HTLV-1 infection, and is therefore a potential target for therapy of 
both ATLL and HAM/TSP.    
 
P30 
 
p30II is a nucleolar protein shown to be important in maintaining high viral loads 
in rabbits inoculated with the ACH molecular clone (Bartoe et al., 2000).  It is a negative 
regulator of viral expression as it selectively retains the doubly spliced tax/rex mRNA in 
the nucleus, preventing its export into the cytoplasm, and thereby decreasing Tax protein 
levels (Nicot et al., 2004).  The specific mechanism by which it keeps the mRNA in the 
nucleus is still unknown.  The current model of p30II activity suggests that it may be 
involved in preventing immune recognition during viral replication, as it reduces 
expression of Tax.  This is supported by in vivo evidence that abrogation of p30II 
prevented the establishment of persistent infection and resulted in lower viral loads 
(Silverman et al., 2004).   
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The p30II protein is also thought to function as a transcription factor as it affects 
the levels of transcription from CREB- and Tax-responsive elements (CREs, TxREs) 
(Zhang et al., 2001; Zhang et al., 2000).  Additionally, Affymetrix microarray gene 
expression analyses of Jurkat cells expressing stably transduced p30II indicated that p30II 
repressed genes involved in cellular gene expression, and enhanced expression of 
regulatory factors (Michael et al., 2004).  Taken together, these data suggest that p30II 
plays an important role in HTLV-1 infection.    
 
HTLV-1 ANTIVIRAL THERAPY 
 
Currently, no effective antiviral therapies exist to treat HTLV-1.  Numerous 
factors have been tested and shown to be effective in inhibiting HTLV-1 replication, but 
none have shown sustained efficacy.  HTLV-1 replication is sensitive to IFN-α, which 
has been shown to prevent Gag association with lipid rafts at the plasma membrane, and 
hence prevent viral assembly (Feng, Heyden, and Ratner, 2003).  Nucleoside analogs, 
such as zidovudine or AZT and lamivudine, have also been tested alone or in 
combination with IFN-α (Gill et al., 1995; Gout et al., 1991; Sheremata et al., 1993; 
Taylor et al., 1999), and though the treatments have shown promise, relapses occur in the 
majority of individuals after discontinuation of therapy.  Other nucleoside reverse 
transcriptase inhibitors (NRTIs) that have been shown to inhibit HTLV-1 replication, in 
culture, are tenofovir, abacavir, zalcitabine, and stavudine (Hill et al., 2003).  Antiviral 
therapies effective against the human immunodeficiency virus type 1 (HIV-1) have been 
tested against HTLV-1.  However, non-nucleoside analogs and protease inhibitors, that 
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are active against HIV-1, are inactive at inhibiting HTLV-1 replication (Pettit et al., 1998; 
Ratner, 2004).  Since inhibitors targeting the HIV-1 co-receptors have recently been 
described (Schols, 2006), the work conducted for this dissertation (Chapter 2) becomes 
even more important, as it could potentially lead to antiviral therapy targets.  Work 
currently being carried with inhibitors to HIV-1 integrase in the Ratner laboratory, by M. 
E. Seegulam, shows that they are effective against HTLV-1 integrase.  Recently, a plant 
derived antiviral protein, pokeweed antiviral protein (PAP), was shown to efficiently 
suppress HTLV-1 gene expression (Mansouri et al., 2009).  PAP depurinated HTLV-1 
genomic RNA and decreased its translational efficiency.  Furthermore, due to the 
decrease in Tax translation, less viral transcription from the viral promoter occurred.  (I 
was co-author on this paper, and contributed to Figures 1B and 1C).  Taken together, it is 
clear that numerous antiviral factors exist and it only remains to be seen if any can be 
used to effectively treat HTLV-1-associated diseases.     
 
HTLV-1 MOLECULAR CLONE 
 
The first functional molecular clone of HTLV-1 was generated in the Ratner 
laboratory (Kimata et al., 1994); since then, two additional molecular clones have been 
described (Derse et al., 1995; Zhao et al., 1995).  Since the clone constructed by Kimata 
et al. (1994) contains a viral genome that is a chimera of two HTLV-1 strains, ATK and 
CH, it was designated ACH.  Upon transfection, the ACH molecular clone produces viral 
particles; these particles are infectious in vitro and in vivo in rabbits, and are capable of 
immortalizing primary CD4+ T lymphocytes (Collins et al., 1996; Kimata et al., 1994). 
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The availability of a functional molecular clone facilitated the work conducted for 
this dissertation (Chapter 3), as it provided the opportunity to study the role of the HTLV-
1 antisense strand in the context of the whole virus.  Specifically, the ACH molecular 
clone was used to examine the effect of the novel viral gene, hbz, on other viral proteins, 
and its role in viral replication.  This study has provided new insights into the complex 
interplay of viral regulatory proteins in HTLV-1 gene expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29 
REFERENCES 
 
Akagi, T., Ono, H., Tsuchida, N., and Shimotohno, K. (1997). Aberrant expression and 
function of p53 in T-cells immortalized by HTLV-I Tax1. FEBS Lett 406(3), 263-
6. 
Al-Fahim, A., Cabre, P., Kastrukoff, L., Dorovini-Zis, K., and Oger, J. (1999). Blood 
mononuclear cells in patients with HTLV-I-associated myelopathy: lymphocytes 
are highly activated and adhesion to endothelial cells is increased. Cell Immunol 
198(1), 1-10. 
Albrecht, B., Collins, N. D., Burniston, M. T., Nisbet, J. W., Ratner, L., Green, P. L., and 
Lairmore, M. D. (2000). Human T-lymphotropic virus type 1 open reading frame 
I p12(I) is required for efficient viral infectivity in primary lymphocytes. J Virol 
74(21), 9828-35. 
Albrecht, B., and Lairmore, M. D. (2002). Critical role of human T-lymphotropic virus 
type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol 
Biol Rev 66(3), 396-406, table of contents. 
Arnold, J., Yamamoto, B., Li, M., Phipps, A. J., Younis, I., Lairmore, M. D., and Green, 
P. L. (2006). Enhancement of infectivity and persistence in vivo by HBZ, a 
natural antisense coded protein of HTLV-1. Blood 107(10), 3976-82. 
Asquith, B., and Bangham, C. R. (2008). How does HTLV-I persist despite a strong cell-
mediated immune response? Trends Immunol 29(1), 4-11. 
Azran, I., Schavinsky-Khrapunsky, Y., and Aboud, M. (2004). Role of Tax protein in 
human T-cell leukemia virus type-I leukemogenicity. Retrovirology 1, 20. 
 30 
Bartoe, J. T., Albrecht, B., Collins, N. D., Robek, M. D., Ratner, L., Green, P. L., and 
Lairmore, M. D. (2000). Functional role of pX open reading frame II of human T-
lymphotropic virus type 1 in maintenance of viral loads in vivo. J Virol 74(3), 
1094-100. 
Basbous, J., Arpin, C., Gaudray, G., Piechaczyk, M., Devaux, C., and Mesnard, J. M. 
(2003). The HBZ factor of human T-cell leukemia virus type I dimerizes with 
transcription factors JunB and c-Jun and modulates their transcriptional activity. J 
Biol Chem 278(44), 43620-7. 
Berneman, Z. N., Gartenhaus, R. B., Reitz, M. S., Jr., Blattner, W. A., Manns, A., 
Hanchard, B., Ikehara, O., Gallo, R. C., and Klotman, M. E. (1992). Expression of 
alternatively spliced human T-lymphotropic virus type I pX mRNA in infected 
cell lines and in primary uncultured cells from patients with adult T-cell 
leukemia/lymphoma and healthy carriers. Proc Natl Acad Sci U S A 89(7), 3005-
9. 
Bobardt, M. D., Saphire, A. C., Hung, H. C., Yu, X., Van der Schueren, B., Zhang, Z., 
David, G., and Gallay, P. A. (2003). Syndecan captures, protects, and transmits 
HIV to T lymphocytes. Immunity 18(1), 27-39. 
Boxus, M., Twizere, J. C., Legros, S., Dewulf, J. F., Kettmann, R., and Willems, L. 
(2008). The HTLV-1 Tax interactome. Retrovirology 5, 76. 
Boxus, M., and Willems, L. (2009). Mechanisms of HTLV-1 persistence and 
transformation. Br J Cancer 101(9), 1497-501. 
 31 
Brady, J., Jeang, K. T., Duvall, J., and Khoury, G. (1987). Identification of p40x-
responsive regulatory sequences within the human T-cell leukemia virus type I 
long terminal repeat. J Virol 61(7), 2175-81. 
Calattini, S., Chevalier, S. A., Duprez, R., Bassot, S., Froment, A., Mahieux, R., and 
Gessain, A. (2005). Discovery of a new human T-cell lymphotropic virus (HTLV-
3) in Central Africa. Retrovirology 2, 30. 
Cavanagh, M. H., Landry, S., Audet, B., Arpin-Andre, C., Hivin, P., Pare, M. E., Thete, 
J., Wattel, E., Marriott, S. J., Mesnard, J. M., and Barbeau, B. (2006). HTLV-I 
antisense transcripts initiating in the 3'LTR are alternatively spliced and 
polyadenylated. Retrovirology 3, 15. 
Ciminale, V., D'Agostino, D. M., Zotti, L., and Chieco-Bianchi, L. (1996). Coding 
potential of the X region of human T-cell leukemia/lymphotropic virus type II. J 
Acquir Immune Defic Syndr Hum Retrovirol 13 Suppl 1, S220-7. 
Ciminale, V., Zotti, L., D'Agostino, D. M., Ferro, T., Casareto, L., Franchini, G., 
Bernardi, P., and Chieco-Bianchi, L. (1999). Mitochondrial targeting of the p13II 
protein coded by the x-II ORF of human T-cell leukemia/lymphotropic virus type 
I (HTLV-I). Oncogene 18(31), 4505-14. 
Clapham, P., Nagy, K., and Weiss, R. A. (1984). Pseudotypes of human T-cell leukemia 
virus types 1 and 2: neutralization by patients' sera. Proc Natl Acad Sci U S A 
81(9), 2886-9. 
Collins, N. D., Newbound, G. C., Albrecht, B., Beard, J. L., Ratner, L., and Lairmore, M. 
D. (1998). Selective ablation of human T-cell lymphotropic virus type 1 p12I 
reduces viral infectivity in vivo. Blood 91(12), 4701-7. 
 32 
Collins, N. D., Newbound, G. C., Ratner, L., and Lairmore, M. D. (1996). In vitro CD4+ 
lymphocyte transformation and infection in a rabbit model with a molecular clone 
of human T-cell lymphotrophic virus type 1. J Virol 70(10), 7241-6. 
Daenke, S., and Booth, S. (2000). Molecular mechanisms affecting HTLV type 1-
dependent fusion at the cell membrane: implications for inhibiting viral 
transmission. AIDS Res Hum Retroviruses 16(16), 1731-6. 
Daenke, S., McCracken, S. A., and Booth, S. (1999). Human T-cell leukaemia/lymphoma 
virus type 1 syncytium formation is regulated in a cell-specific manner by ICAM-
1, ICAM-3 and VCAM-1 and can be inhibited by antibodies to integrin beta2 or 
beta7. J Gen Virol 80 ( Pt 6), 1429-36. 
de The, G., and Kazanji, M. (1996). An HTLV-I/II vaccine: from animal models to 
clinical trials? J Acquir Immune Defic Syndr Hum Retrovirol 13 Suppl 1, S191-8. 
Delamarre, L., Rosenberg, A. R., Pique, C., Pham, D., Callebaut, I., and Dokhelar, M. C. 
(1996). The HTLV-I envelope glycoproteins: structure and functions. J Acquir 
Immune Defic Syndr Hum Retrovirol 13 Suppl 1, S85-91. 
Denesvre, C., Sonigo, P., Corbin, A., Ellerbrok, H., and Sitbon, M. (1995). Influence of 
transmembrane domains on the fusogenic abilities of human and murine leukemia 
retrovirus envelopes. J Virol 69(7), 4149-57. 
Derse, D., Mikovits, J., Polianova, M., Felber, B. K., and Ruscetti, F. (1995). Virions 
released from cells transfected with a molecular clone of human T-cell leukemia 
virus type I give rise to primary and secondary infections of T cells. J Virol 69(3), 
1907-12. 
 33 
Felber, B. K., Paskalis, H., Kleinman-Ewing, C., Wong-Staal, F., and Pavlakis, G. N. 
(1985). The pX protein of HTLV-I is a transcriptional activator of its long 
terminal repeats. Science 229(4714), 675-9. 
Feng, X., Heyden, N. V., and Ratner, L. (2003). Alpha interferon inhibits human T-cell 
leukemia virus type 1 assembly by preventing Gag interaction with rafts. J Virol 
77(24), 13389-95. 
Franchini, G. (1995). Molecular mechanisms of human T-cell leukemia/lymphotropic 
virus type I infection. Blood 86(10), 3619-39. 
Fukumoto, R., Andresen, V., Bialuk, I., Cecchinato, V., Walser, J. C., Valeri, V. W., 
Nauroth, J. M., Gessain, A., Nicot, C., and Franchini, G. (2009). In vivo genetic 
mutations define predominant functions of the human T-cell leukemia/lymphoma 
virus p12I protein. Blood 113(16), 3726-34. 
Furukawa, K., and Shiku, H. (1991). Alternatively spliced mRNA of the pX region of 
human T lymphotropic virus type I proviral genome. FEBS Lett 295(1-3), 141-5. 
Furukawa, Y., Kubota, R., Tara, M., Izumo, S., and Osame, M. (2001). Existence of 
escape mutant in HTLV-I tax during the development of adult T-cell leukemia. 
Blood 97(4), 987-93. 
Gachon, F., Thebault, S., Peleraux, A., Devaux, C., and Mesnard, J. M. (2000). 
Molecular interactions involved in the transactivation of the human T-cell 
leukemia virus type 1 promoter mediated by Tax and CREB-2 (ATF-4). Mol Cell 
Biol 20(10), 3470-81. 
Gallo, R. C. (2005). The discovery of the first human retrovirus: HTLV-1 and HTLV-2. 
Retrovirology 2, 17. 
 34 
Gallo, R. C., Sliski, A., and Wong-Staal, F. (1983). Origin of human T-cell leukaemia-
lymphoma virus. Lancet 2(8356), 962-3. 
Gartenhaus, R. B., and Wang, P. (1995). Functional inactivation of wild-type p53 protein 
correlates with loss of IL-2 dependence in HTLV-I transformed human T 
lymphocytes. Leukemia 9(12), 2082-6. 
Gatza, M. L., Watt, J. C., and Marriott, S. J. (2003). Cellular transformation by the 
HTLV-I Tax protein, a jack-of-all-trades. Oncogene 22(33), 5141-9. 
Gaudray, G., Gachon, F., Basbous, J., Biard-Piechaczyk, M., Devaux, C., and Mesnard, J. 
M. (2002). The complementary strand of the human T-cell leukemia virus type 1 
RNA genome encodes a bZIP transcription factor that down-regulates viral 
transcription. J Virol 76(24), 12813-22. 
Gavalchin, J., Fan, N., Waterbury, P. G., Corbett, E., Faldasz, B. D., Peshick, S. M., 
Poiesz, B. J., Papsidero, L., and Lane, M. J. (1995). Regional localization of the 
putative cell surface receptor for HTLV-I to human chromosome 17q23.2-
17q25.3. Virology 212(1), 196-203. 
Gessain, A., Gallo, R. C., and Franchini, G. (1992). Low degree of human T-cell 
leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring 
viral transmission and movement of ancient human populations. J Virol 66(4), 
2288-95. 
Ghez, D., Lepelletier, Y., Lambert, S., Fourneau, J. M., Blot, V., Janvier, S., Arnulf, B., 
van Endert, P. M., Heveker, N., Pique, C., and Hermine, O. (2006). Neuropilin-1 
is involved in human T-cell lymphotropic virus type 1 entry. J Virol 80(14), 6844-
54. 
 35 
Giebler, H. A., Loring, J. E., van Orden, K., Colgin, M. A., Garrus, J. E., Escudero, K. 
W., Brauweiler, A., and Nyborg, J. K. (1997). Anchoring of CREB binding 
protein to the human T-cell leukemia virus type 1 promoter: a molecular 
mechanism of Tax transactivation. Mol Cell Biol 17(9), 5156-64. 
Gill, P. S., Harrington, W., Jr., Kaplan, M. H., Ribeiro, R. C., Bennett, J. M., Liebman, H. 
A., Bernstein-Singer, M., Espina, B. M., Cabral, L., Allen, S., and et al. (1995). 
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon 
alfa and zidovudine. N Engl J Med 332(26), 1744-8. 
Gout, O., Gessain, A., Iba-Zizen, M., Kouzan, S., Bolgert, F., de The, G., and Lyon-
Caen, O. (1991). The effect of zidovudine on chronic myelopathy associated with 
HTLV-1. J Neurol 238(2), 108-9. 
Grassmann, R., Aboud, M., and Jeang, K. T. (2005). Molecular mechanisms of cellular 
transformation by HTLV-1 Tax. Oncogene 24(39), 5976-85. 
Heger, P., Rosorius, O., Hauber, J., and Stauber, R. H. (1999). Titration of cellular export 
factors, but not heteromultimerization, is the molecular mechanism of trans-
dominant HTLV-1 rex mutants. Oncogene 18(28), 4080-90. 
Hidaka, M., Inoue, J., Yoshida, M., and Seiki, M. (1988). Post-transcriptional regulator 
(rex) of HTLV-1 initiates expression of viral structural proteins but suppresses 
expression of regulatory proteins. EMBO J 7(2), 519-23. 
Hildreth, J. E. (1998). Syncytium-inhibiting monoclonal antibodies produced against 
human T-cell lymphotropic virus type 1-infected cells recognize class II major 
histocompatibility complex molecules and block by protein crowding. J Virol 
72(12), 9544-52. 
 36 
Hildreth, J. E., Subramanium, A., and Hampton, R. A. (1997). Human T-cell 
lymphotropic virus type 1 (HTLV-1)-induced syncytium formation mediated by 
vascular cell adhesion molecule-1: evidence for involvement of cell adhesion 
molecules in HTLV-1 biology. J Virol 71(2), 1173-80. 
Hill, S. A., Lloyd, P. A., McDonald, S., Wykoff, J., and Derse, D. (2003). Susceptibility 
of human T cell leukemia virus type I to nucleoside reverse transcriptase 
inhibitors. J Infect Dis 188(3), 424-7. 
Hivin, P., Frederic, M., Arpin-Andre, C., Basbous, J., Gay, B., Thebault, S., and 
Mesnard, J. M. (2005). Nuclear localization of HTLV-I bZIP factor (HBZ) is 
mediated by three distinct motifs. J Cell Sci 118(Pt 7), 1355-62. 
Igakura, T., Stinchcombe, J. C., Goon, P. K., Taylor, G. P., Weber, J. N., Griffiths, G. M., 
Tanaka, Y., Osame, M., and Bangham, C. R. (2003). Spread of HTLV-I between 
lymphocytes by virus-induced polarization of the cytoskeleton. Science 
299(5613), 1713-6. 
Imai, T., Fukudome, K., Takagi, S., Nagira, M., Furuse, M., Fukuhara, N., Nishimura, 
M., Hinuma, Y., and Yoshie, O. (1992). C33 antigen recognized by monoclonal 
antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium 
formation is a member of a new family of transmembrane proteins including 
CD9, CD37, CD53, and CD63. J Immunol 149(9), 2879-86. 
Jain, P., Manuel, S. L., Khan, Z. K., Ahuja, J., Quann, K., and Wigdahl, B. (2009). DC-
SIGN mediates cell-free infection and transmission of human T-cell lymphotropic 
virus type 1 by dendritic cells. J Virol 83(21), 10908-21. 
 37 
Jassal, S. R., Pohler, R. G., and Brighty, D. W. (2001). Human T-cell leukemia virus type 
1 receptor expression among syncytium-resistant cell lines revealed by a novel 
surface glycoprotein-immunoadhesin. J Virol 75(17), 8317-28. 
Jeang, K. T., Giam, C. Z., Majone, F., and Aboud, M. (2004). Life, death, and tax: role of 
HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol 
Chem 279(31), 31991-4. 
Jones, K. S., Petrow-Sadowski, C., Bertolette, D. C., Huang, Y., and Ruscetti, F. W. 
(2005). Heparan sulfate proteoglycans mediate attachment and entry of human T-
cell leukemia virus type 1 virions into CD4+ T cells. J Virol 79(20), 12692-702. 
Jones, K. S., Petrow-Sadowski, C., Huang, Y. K., Bertolette, D. C., and Ruscetti, F. W. 
(2008). Cell-free HTLV-1 infects dendritic cells leading to transmission and 
transformation of CD4(+) T cells. Nat Med 14(4), 429-36. 
Kalyanaraman, V. S., Sarngadharan, M. G., Robert-Guroff, M., Miyoshi, I., Golde, D., 
and Gallo, R. C. (1982). A new subtype of human T-cell leukemia virus (HTLV-
II) associated with a T-cell variant of hairy cell leukemia. Science 218(4572), 
571-3. 
Kashanchi, F., and Brady, J. N. (2005). Transcriptional and post-transcriptional gene 
regulation of HTLV-1. Oncogene 24(39), 5938-51. 
Kimata, J. T., Wong, F. H., Wang, J. J., and Ratner, L. (1994). Construction and 
characterization of infectious human T-cell leukemia virus type 1 molecular 
clones. Virology 204(2), 656-64. 
Koiwa, T., Hamano-Usami, A., Ishida, T., Okayama, A., Yamaguchi, K., Kamihira, S., 
and Watanabe, T. (2002). 5'-long terminal repeat-selective CpG methylation of 
 38 
latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. J Virol 
76(18), 9389-97. 
Koralnik, I. J., Boeri, E., Saxinger, W. C., Monico, A. L., Fullen, J., Gessain, A., Guo, H. 
G., Gallo, R. C., Markham, P., Kalyanaraman, V., and et al. (1994). Phylogenetic 
associations of human and simian T-cell leukemia/lymphotropic virus type I 
strains: evidence for interspecies transmission. J Virol 68(4), 2693-707. 
Koralnik, I. J., Gessain, A., Klotman, M. E., Lo Monico, A., Berneman, Z. N., and 
Franchini, G. (1992). Protein isoforms encoded by the pX region of human T-cell 
leukemia/lymphotropic virus type I. Proc Natl Acad Sci U S A 89(18), 8813-7. 
Kuhlmann, A. S., Villaudy, J., Gazzolo, L., Castellazzi, M., Mesnard, J. M., and Duc 
Dodon, M. (2007). HTLV-1 HBZ cooperates with JunD to enhance transcription 
of the human telomerase reverse transcriptase gene (hTERT). Retrovirology 4, 92. 
Lairmore, M. D., Albrecht, B., D'Souza, C., Nisbet, J. W., Ding, W., Bartoe, J. T., Green, 
P. L., and Zhang, W. (2000). In vitro and in vivo functional analysis of human T 
cell lymphotropic virus type 1 pX open reading frames I and II. AIDS Res Hum 
Retroviruses 16(16), 1757-64. 
Lambert, S., Bouttier, M., Vassy, R., Seigneuret, M., Petrow-Sadowski, C., Janvier, S., 
Heveker, N., Ruscetti, F. W., Perret, G., Jones, K. S., and Pique, C. (2009). 
HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of 
VEGF165. Blood 113(21), 5176-85. 
Landry, S., Halin, M., Vargas, A., Lemasson, I., Mesnard, J. M., and Barbeau, B. (2009). 
Upregulation of human T-cell leukemia virus type 1 antisense transcription by the 
viral tax protein. J Virol 83(4), 2048-54. 
 39 
Larocca, D., Chao, L. A., Seto, M. H., and Brunck, T. K. (1989). Human T-cell leukemia 
virus minus strand transcription in infected T-cells. Biochem Biophys Res 
Commun 163(2), 1006-13. 
Lefebvre, L., Vanderplasschen, A., Ciminale, V., Heremans, H., Dangoisse, O., Jauniaux, 
J. C., Toussaint, J. F., Zelnik, V., Burny, A., Kettmann, R., and Willems, L. 
(2002). Oncoviral bovine leukemia virus G4 and human T-cell leukemia virus 
type 1 p13(II) accessory proteins interact with farnesyl pyrophosphate synthetase. 
J Virol 76(3), 1400-14. 
Mahieux, R., and Gessain, A. (2009). The human HTLV-3 and HTLV-4 retroviruses: 
new members of the HTLV family. Pathol Biol (Paris) 57(2), 161-6. 
Majorovits, E., Nejmeddine, M., Tanaka, Y., Taylor, G. P., Fuller, S. D., and Bangham, 
C. R. (2008). Human T-lymphotropic virus-1 visualized at the virological synapse 
by electron tomography. PLoS One 3(5), e2251. 
Manel, N., Battini, J. L., Taylor, N., and Sitbon, M. (2005). HTLV-1 tropism and 
envelope receptor. Oncogene 24(39), 6016-25. 
Manel, N., Kim, F. J., Kinet, S., Taylor, N., Sitbon, M., and Battini, J. L. (2003). The 
ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 115(4), 449-
59. 
Manns, A., Hisada, M., and La Grenade, L. (1999). Human T-lymphotropic virus type I 
infection. Lancet 353(9168), 1951-8. 
Mansouri, S., Choudhary, G., Sarzala, P. M., Ratner, L., and Hudak, K. A. (2009). 
Suppression of human T-cell leukemia virus I gene expression by pokeweed 
antiviral protein. J Biol Chem 284(45), 31453-62. 
 40 
Marriott, S. J., and Semmes, O. J. (2005). Impact of HTLV-I Tax on cell cycle 
progression and the cellular DNA damage repair response. Oncogene 24(39), 
5986-95. 
Matsumoto, J., Ohshima, T., Isono, O., and Shimotohno, K. (2005). HTLV-1 HBZ 
suppresses AP-1 activity by impairing both the DNA-binding ability and the 
stability of c-Jun protein. Oncogene 24(6), 1001-10. 
Matsuoka, M., and Green, P. L. (2009). The HBZ gene, a key player in HTLV-1 
pathogenesis. Retrovirology 6, 71. 
Matsuoka, M., and Jeang, K. T. (2005). Human T-cell leukemia virus type I at age 25: a 
progress report. Cancer Res 65(11), 4467-70. 
Matsuoka, M., and Jeang, K. T. (2007). Human T-cell leukaemia virus type 1 (HTLV-1) 
infectivity and cellular transformation. Nat Rev Cancer 7(4), 270-80. 
Michael, B., Nair, A. M., Hiraragi, H., Shen, L., Feuer, G., Boris-Lawrie, K., and 
Lairmore, M. D. (2004). Human T lymphotropic virus type-1 p30II alters cellular 
gene expression to selectively enhance signaling pathways that activate T 
lymphocytes. Retrovirology 1, 39. 
Miyazaki, M., Yasunaga, J., Taniguchi, Y., Tamiya, S., Nakahata, T., and Matsuoka, M. 
(2007). Preferential selection of human T-cell leukemia virus type 1 provirus 
lacking the 5' long terminal repeat during oncogenesis. J Virol 81(11), 5714-23. 
Murata, K., Hayashibara, T., Sugahara, K., Uemura, A., Yamaguchi, T., Harasawa, H., 
Hasegawa, H., Tsuruda, K., Okazaki, T., Koji, T., Miyanishi, T., Yamada, Y., and 
Kamihira, S. (2006). A novel alternative splicing isoform of human T-cell 
 41 
leukemia virus type 1 bZIP factor (HBZ-SI) targets distinct subnuclear 
localization. J Virol 80(5), 2495-505. 
Nicot, C., Dundr, M., Johnson, J. M., Fullen, J. R., Alonzo, N., Fukumoto, R., Princler, 
G. L., Derse, D., Misteli, T., and Franchini, G. (2004). HTLV-1-encoded p30II is 
a post-transcriptional negative regulator of viral replication. Nat Med 10(2), 197-
201. 
Nicot, C., Harrod, R. L., Ciminale, V., and Franchini, G. (2005). Human T-cell 
leukemia/lymphoma virus type 1 nonstructural genes and their functions. 
Oncogene 24(39), 6026-34. 
Nicot, C., Mulloy, J. C., Ferrari, M. G., Johnson, J. M., Fu, K., Fukumoto, R., Trovato, 
R., Fullen, J., Leonard, W. J., and Franchini, G. (2001). HTLV-1 p12(I) protein 
enhances STAT5 activation and decreases the interleukin-2 requirement for 
proliferation of primary human peripheral blood mononuclear cells. Blood 98(3), 
823-9. 
Niyogi, K., and Hildreth, J. E. (2001). Characterization of new syncytium-inhibiting 
monoclonal antibodies implicates lipid rafts in human T-cell leukemia virus type 
1 syncytium formation. J Virol 75(16), 7351-61. 
Okochi, K., Sato, H., and Hinuma, Y. (1984). A retrospective study on transmission of 
adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox 
Sang 46(5), 245-53. 
Okuma, K., Dalton, K. P., Buonocore, L., Ramsburg, E., and Rose, J. K. (2003). 
Development of a novel surrogate virus for human T-cell leukemia virus type 1: 
inhibition of infection by osteoprotegerin. J Virol 77(15), 8562-9. 
 42 
Paine, E., Gu, R., and Ratner, L. (1994). Structure and expression of the human T-cell 
leukemia virus type 1 envelope protein. Virology 199(2), 331-8. 
Pettit, S. C., Sanchez, R., Smith, T., Wehbie, R., Derse, D., and Swanstrom, R. (1998). 
HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected 
cells. AIDS Res Hum Retroviruses 14(11), 1007-14. 
Pinon, J. D., Klasse, P. J., Jassal, S. R., Welson, S., Weber, J., Brighty, D. W., and 
Sattentau, Q. J. (2003). Human T-cell leukemia virus type 1 envelope 
glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J 
Virol 77(18), 9922-30. 
Pique, C., Lagaudriere-Gesbert, C., Delamarre, L., Rosenberg, A. R., Conjeaud, H., and 
Dokhelar, M. C. (2000a). Interaction of CD82 tetraspanin proteins with HTLV-1 
envelope glycoproteins inhibits cell-to-cell fusion and virus transmission. 
Virology 276(2), 455-65. 
Pique, C., Tursz, T., and Dokhelar, M. C. (1990). Mutations introduced along the HTLV-
I envelope gene result in a non-functional protein: a basis for envelope 
conservation? EMBO J 9(13), 4243-8. 
Pique, C., Ureta-Vidal, A., Gessain, A., Chancerel, B., Gout, O., Tamouza, R., Agis, F., 
and Dokhelar, M. C. (2000b). Evidence for the chronic in vivo production of 
human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T 
lymphocytes directed against viral peptides. J Exp Med 191(3), 567-72. 
Pise-Masison, C. A., Mahieux, R., Radonovich, M., Jiang, H., and Brady, J. N. (2001). 
Human T-lymphotropic virus type I Tax protein utilizes distinct pathways for p53 
inhibition that are cell type-dependent. J Biol Chem 276(1), 200-5. 
 43 
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., and Gallo, R. C. 
(1980). Detection and isolation of type C retrovirus particles from fresh and 
cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl 
Acad Sci U S A 77(12), 7415-9. 
Proietti, F. A., Carneiro-Proietti, A. B., Catalan-Soares, B. C., and Murphy, E. L. (2005). 
Global epidemiology of HTLV-I infection and associated diseases. Oncogene 
24(39), 6058-68. 
Ratner, L. (2004). Adult T cell leukemia lymphoma. Front Biosci 9, 2852-9. 
Reddy, T. R., Tang, H., Li, X., and Wong-Staal, F. (1997). Functional interaction of the 
HTLV-1 transactivator Tax with activating transcription factor-4 (ATF4). 
Oncogene 14(23), 2785-92. 
Reid, R. L., Lindholm, P. F., Mireskandari, A., Dittmer, J., and Brady, J. N. (1993). 
Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. 
Oncogene 8(11), 3029-36. 
Sagara, Y., Inoue, Y., Kojima, E., Ishida, C., Shiraki, H., and Maeda, Y. (2001). 
Phosphatidylglycerol participates in syncytium formation induced by HTLV type 
1-bearing cells. AIDS Res Hum Retroviruses 17(2), 125-35. 
Sagara, Y., Ishida, C., Inoue, Y., Shiraki, H., and Maeda, Y. (1998). 71-kilodalton heat 
shock cognate protein acts as a cellular receptor for syncytium formation induced 
by human T-cell lymphotropic virus type 1. J Virol 72(1), 535-41. 
Saito, M., Matsuzaki, T., Satou, Y., Yasunaga, J., Saito, K., Arimura, K., Matsuoka, M., 
and Ohara, Y. (2009). In vivo expression of the HBZ gene of HTLV-1 correlates 
with proviral load, inflammatory markers and disease severity in HTLV-1 
 44 
associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 6, 
19. 
Satou, Y., and Matsuoka, M. (2007). Implication of the HTLV-I bZIP factor gene in the 
leukemogenesis of adult T-cell leukemia. Int J Hematol 86(2), 107-12. 
Satou, Y., Yasunaga, J., Yoshida, M., and Matsuoka, M. (2006). HTLV-I basic leucine 
zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. 
Proc Natl Acad Sci U S A 103(3), 720-5. 
Schols, D. (2006). HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral 
Res 71(2-3), 216-26. 
Sheremata, W. A., Benedict, D., Squilacote, D. C., Sazant, A., and DeFreitas, E. (1993). 
High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and 
possible efficacy. Neurology 43(10), 2125-9. 
Silic-Benussi, M., Biasiotto, R., Andresen, V., Franchini, G., D'Agostino, D. M., and 
Ciminale, V. (2010). HTLV-1 p13, a small protein with a busy agenda. Mol 
Aspects Med. 
Silverman, L. R., Phipps, A. J., Montgomery, A., Ratner, L., and Lairmore, M. D. (2004). 
Human T-cell lymphotropic virus type 1 open reading frame II-encoded p30II is 
required for in vivo replication: evidence of in vivo reversion. J Virol 78(8), 
3837-45. 
Sommerfelt, M. A., and Weiss, R. A. (1990). Receptor interference groups of 20 
retroviruses plating on human cells. Virology 176(1), 58-69. 
 45 
Sommerfelt, M. A., Williams, B. P., Clapham, P. R., Solomon, E., Goodfellow, P. N., 
and Weiss, R. A. (1988). Human T cell leukemia viruses use a receptor 
determined by human chromosome 17. Science 242(4885), 1557-9. 
Spillmann, D. (2001). Heparan sulfate: anchor for viral intruders? Biochimie 83(8), 811-
7. 
Takeda, S., Maeda, M., Morikawa, S., Taniguchi, Y., Yasunaga, J., Nosaka, K., Tanaka, 
Y., and Matsuoka, M. (2004). Genetic and epigenetic inactivation of tax gene in 
adult T-cell leukemia cells. Int J Cancer 109(4), 559-67. 
Takenouchi, N., Jones, K. S., Lisinski, I., Fugo, K., Yao, K., Cushman, S. W., Ruscetti, 
F. W., and Jacobson, S. (2007). GLUT1 is not the primary binding receptor but is 
associated with cell-to-cell transmission of human T-cell leukemia virus type 1. J 
Virol 81(3), 1506-10. 
Tamiya, S., Matsuoka, M., Etoh, K., Watanabe, T., Kamihira, S., Yamaguchi, K., and 
Takatsuki, K. (1996). Two types of defective human T-lymphotropic virus type I 
provirus in adult T-cell leukemia. Blood 88(8), 3065-73. 
Taniguchi, Y., Nosaka, K., Yasunaga, J., Maeda, M., Mueller, N., Okayama, A., and 
Matsuoka, M. (2005). Silencing of human T-cell leukemia virus type I gene 
transcription by epigenetic mechanisms. Retrovirology 2, 64. 
Taylor, G. P., Hall, S. E., Navarrete, S., Michie, C. A., Davis, R., Witkover, A. D., 
Rossor, M., Nowak, M. A., Rudge, P., Matutes, E., Bangham, C. R., and Weber, 
J. N. (1999). Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-
1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency 
in patients with HTLV-1-associated myelopathy. J Virol 73(12), 10289-95. 
 46 
Thebault, S., Basbous, J., Hivin, P., Devaux, C., and Mesnard, J. M. (2004). HBZ 
interacts with JunD and stimulates its transcriptional activity. FEBS Lett 562(1-3), 
165-70. 
Trejo, S. R., and Ratner, L. (2000). The HTLV receptor is a widely expressed protein. 
Virology 268(1), 41-8. 
Uchida, N., Otsuka, T., Arima, F., Shigematsu, H., Fukuyama, T., Maeda, M., Sugio, Y., 
Itoh, Y., and Niho, Y. (1999). Correlation of telomerase activity with 
development and progression of adult T-cell leukemia. Leuk Res 23(3), 311-6. 
Uchiyama, T., Ishikawa, T., and Imura, A. (1996). Cell adhesion molecules in HTLV-I 
infection. J Acquir Immune Defic Syndr Hum Retrovirol 13 Suppl 1, S114-8. 
Usui, T., Yanagihara, K., Tsukasaki, K., Murata, K., Hasegawa, H., Yamada, Y., and 
Kamihira, S. (2008). Characteristic expression of HTLV-1 basic zipper factor 
(HBZ) transcripts in HTLV-1 provirus-positive cells. Retrovirology 5, 34. 
Vandamme, A. M., Salemi, M., and Desmyter, J. (1998). The simian origins of the 
pathogenic human T-cell lymphotropic virus type I. Trends Microbiol 6(12), 477-
83. 
Weiss, R. A., Clapham, P., Nagy, K., and Hoshino, H. (1985). Envelope properties of 
human T-cell leukemia viruses. Curr Top Microbiol Immunol 115, 235-46. 
Wielgosz, M. M., Rauch, D. A., Jones, K. S., Ruscetti, F. W., and Ratner, L. (2005). 
Cholesterol dependence of HTLV-I infection. AIDS Res Hum Retroviruses 21(1), 
43-50. 
Wolfe, N. D., Heneine, W., Carr, J. K., Garcia, A. D., Shanmugam, V., Tamoufe, U., 
Torimiro, J. N., Prosser, A. T., Lebreton, M., Mpoudi-Ngole, E., McCutchan, F. 
 47 
E., Birx, D. L., Folks, T. M., Burke, D. S., and Switzer, W. M. (2005). Emergence 
of unique primate T-lymphotropic viruses among central African bushmeat 
hunters. Proc Natl Acad Sci U S A 102(22), 7994-9. 
Yamato, K., Oka, T., Hiroi, M., Iwahara, Y., Sugito, S., Tsuchida, N., and Miyoshi, I. 
(1993). Aberrant expression of the p53 tumor suppressor gene in adult T-cell 
leukemia and HTLV-I-infected cells. Jpn J Cancer Res 84(1), 4-8. 
Yin, M. J., and Gaynor, R. B. (1996). Complex formation between CREB and Tax 
enhances the binding affinity of CREB for the human T-cell leukemia virus type 1 
21-base-pair repeats. Mol Cell Biol 16(6), 3156-68. 
Yoshida, M. (2001). Multiple viral strategies of HTLV-1 for dysregulation of cell growth 
control. Annu Rev Immunol 19, 475-96. 
Yoshida, M., Satou, Y., Yasunaga, J., Fujisawa, J., and Matsuoka, M. (2008). 
Transcriptional control of spliced and unspliced human T-cell leukemia virus type 
1 bZIP factor (HBZ) gene. J Virol 82(19), 9359-68. 
Zhang, W., Nisbet, J. W., Albrecht, B., Ding, W., Kashanchi, F., Bartoe, J. T., and 
Lairmore, M. D. (2001). Human T-lymphotropic virus type 1 p30(II) regulates 
gene transcription by binding CREB binding protein/p300. J Virol 75(20), 9885-
95. 
Zhang, W., Nisbet, J. W., Bartoe, J. T., Ding, W., and Lairmore, M. D. (2000). Human T-
lymphotropic virus type 1 p30(II) functions as a transcription factor and 
differentially modulates CREB-responsive promoters. J Virol 74(23), 11270-7. 
 48 
Zhao, T., Yasunaga, J., Satou, Y., Nakao, M., Takahashi, M., Fujii, M., and Matsuoka, 
M. (2009). Human T-cell leukemia virus type 1 bZIP factor selectively suppresses 
the classical pathway of NF-kappaB. Blood 113(12), 2755-64. 
Zhao, T. M., Robinson, M. A., Bowers, F. S., and Kindt, T. J. (1995). Characterization of 
an infectious molecular clone of human T-cell leukemia virus type I. J Virol 
69(4), 2024-30. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
Chapter 2 
 
 
 
 
A Functional Retroviral cDNA Library Screen to 
Identify the Receptor/Attachment Factor for 
HTLV-1 
 
 
 
 
 
 
 
 
 
 50 
Preface to Chapter 2 
Screen 1 described in this chapter was carried out in its entirety by G.C.  Screen 2 
described in this chapter was carried out by the following: G.C., Dan Rauch, Intelly Lee, 
and Angelique Cerceilleux. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51 
ABSTRACT 
The receptor for human T-cell leukemia virus type 1 (HTLV-1) is still unknown.  
Since viral envelope-receptor interactions are important in determining viral tropism, and 
the expression of a receptor on specific cells can determine the route of viral entry, the 
pattern of viral spread, and the resulting pathogenesis, it is vital to find the receptor for 
HTLV-1.  We designed a retroviral cDNA library screen in which we introduced the 
cDNA from the permissive HeLa S3 cell line into the poorly susceptible NIH 3T3 cell 
line.  The NIH 3T3 cells were selected after infection with HTLV-1 Env pseudotyped 
viral particles, carrying a drug resistance gene.  We isolated approximately 460 cDNAs, 
which were sequenced and subjected to sequence analysis.  Of these, 20 were selected as 
potential, high-priority HTLV-1 receptor candidates, based on the number of times they 
were identified, whether they were membrane proteins, and whether they were previously 
identified as HIV-dependency factors.  These candidates are currently being tested to 
determine if any are the receptor for HTLV-1.   
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INTRODUCTION 
 
Human T cell leukemia virus type 1 (HTLV-1) is a complex retrovirus belonging 
to the Deltaretrovirus family.  It is widespread and the etiologic agent of adult T cell 
leukemia/lymphoma (ATLL) (Hinuma et al., 1981; Poiesz et al., 1980), a malignancy of 
CD4+ T lymphocytes, and a chronic neurological disorder termed HTLV-1-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP) (Bhagavati et al., 1988; Gessain et 
al., 1985; Osame et al., 1987).  In individuals exposed to HTLV-1, those with high virus 
loads are at the greatest risk of developing this disease. In vivo, HTLV-1 primarily infects 
CD4+ T cells, though other hematopoietic cells (CD8+ T cells, B lymphocytes, 
monocytes/macrophages, dendritic cells, and megakaryocytes) and glial cells (astrocytes 
and microglial cells) have been shown to be infected (Eiraku et al., 1998; Grant et al., 
2002; Hanon et al., 2000; Koyanagi et al., 1993; Lehky et al., 1995; Levin et al., 1997; 
Macatonia et al., 1992; Nagai et al., 2001).  In vitro, however, the HTLV-1 envelope 
(Env) has a much broader tropism (Jassal, Pohler, and Brighty, 2001; Trejo and Ratner, 
2000).   
To date, no molecule has been definitively identified as the receptor utilized by 
HTLV-1 to enter and infect vertebrate cells.  The broad in vitro tropism is one of the 
reasons the search for the receptor has been challenging.  The fact that the HTLV-1 Env 
is highly fusogenic and cytotoxic, coupled with the technical difficulty of producing high 
titers of cell-free virus, has complicated efforts in identifying the receptor.  Over the 
years, several candidate proteins have been proposed as the receptor for HTLV-1 or an 
adhesion molecule that promotes infection, including interleukin-2 receptor α (Lando et 
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al., 1983), heat shock protein Hsc70 (Sagara et al., 1998), vascular cell adhesion 
molecule-1 (Hildreth, Subramanium, and Hampton, 1997), tetraspanin C33 (Imai et al., 
1992), and an 80-kDa glycoprotein analog of intercellular adhesion molecule-3 
(Agadjanyan et al., 1994).  However, the in vitro tropism of HTLV-1 Env pseudotyped 
HIV-1, and the binding pattern of soluble HTLV-1 Env did not support the role of these 
proteins as receptors for the virus (Jassal et al., 2001; Jassal, Pohler, and Brighty, 2001; 
Trejo and Ratner, 2000).  Recent studies from several laboratories have identified 
molecules on the cell surface that may enhance HTLV-1 entry, but their roles in 
enhancing infection are unclear. 
Manel et al. identified glucose transporter 1 (GLUT-1) as the HTLV receptor 
based on their observation that cells transfected with HTLV-1 or -2 Env blocked 
acidification of the media by altering lactate production and glucose transport (Manel et 
al., 2003).  However, the data presented did not conclusively establish GLUT-1 as the 
receptor for HTLV-1, since (i) most of the data presented were based on HTLV-2, and 
(ii) the studies with HTLV-1 did not show a significant increase in binding and infection 
in the presence of GLUT-1.  Furthermore, infection studies carried out in our lab using 
GLUT-1 as the receptor, showed no more than a 40-fold increase in infection of a non-
susceptible cell-line (compared to a more than 8000-fold increase in infection of a 
permissive cell-line).  A subsequent paper similarly questioned the role of GLUT-1 as the 
primary binding receptor for HTLV-1 by showing that activated CD4+ T cells, that were 
susceptible to HTLV-1 infection, expressed undetectable levels of surface GLUT-1 
(Takenouchi et al., 2007).  However, they did report that GLUT-1 enhanced HTLV-1 
cell-to-cell transmission, leading to the theory that other factors may be required, in 
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conjunction with GLUT-1, for efficient Env-binding and fusion.  This led to a number of 
studies, with a diverse set of conclusions. 
One paper showed that heparan sulfate proteoglycans (HSPGs) mediated 
attachment and entry of HTLV-1 into CD4+ T cells (Jones et al., 2005), while another 
paper showed that HTLV-1 uses HSPGs and neuropilin-1 (NRP-1), a co-receptor for 
certain isoforms of vascular endothelial growth factor (VEGF), for entry (Lambert et al., 
2009).  Two other studies presented data that suggested that HTLV-1 uses both NRP-1 
and GLUT-1, individually or collectively, to infect a variety of cell types (Ghez et al., 
2006; Jin et al., 2009).  The most recent study analyzed potential HTLV-1 receptors 
(Sagara et al., 1996) and suggested that a fourth molecule, DC-specific intercellular 
adhesion molecule-3 (ICAM-3)-grabbing nonintegrin (DC-SIGN), plays a critical role in 
HTLV-1 binding, transmission, and infection (Jain et al., 2009).  It is evident from this 
plethora of data that there are a number of factors that work to enhance HTLV-1 binding 
and transmission, but it is unclear if any serve as the receptor for HTLV-1. 
To approach this problem systematically, we designed a retroviral cDNA library 
screen that introduces cDNA from highly susceptible HeLa S3 cells into the poorly 
susceptible murine NIH 3T3 cells.  We identified approximately 460 cDNAs from this 
screen, of which 20 were selected as potential, high-priority HTLV-1 receptor candidates. 
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RESULTS 
 
The retroviral cDNA library screen 
 
We developed a retroviral cDNA library screen to detect proteins that could 
potentially serve as the receptor(s), attachment factor(s), or entry-enhancing molecule(s) 
for HTLV-1.  The premise of the screen was to introduce a cDNA library from cells 
highly susceptible to HTLV-1 infection into poorly infectious cells, infect the resulting 
cDNA-expressing cells with HTLV-1 pseudotyped viral particles, select for cells that 
permitted infection, and isolate any cDNAs expressed in those cells.  Based on previous 
work (Jassal, Pohler, and Brighty, 2001; Trejo and Ratner, 2000), and current studies 
(Fig. 1), we used the murine NIH 3T3 cells as the poorly susceptible cell line.  We 
generated HTLV-1 Env, A-MLV Env, and VSVg pseudotyped HIV-luc particles and 
infected 293T and NIH 3T3 cells.  Two days later we carried out luciferase assays on 
these cells and determined the level of entry, based on luciferase levels.  As shown in Fig. 
1, 293T cells were readily infected by all three envelopes, whereas the NIH 3T3 cells 
were permissive to the A-MLV Env and VSVg, and poorly susceptible to the HTLV-1 
Env.   
On our first attempt, we used a retroviral cDNA library from human brain.  We 
isolated 240 cDNA-infected colonies and 120 background colonies.  All 360 colonies 
were expanded and their susceptibility to HTLV-1 Env tested with HIV-luc (HTLV-1).  
Based on the luciferase data, we selected seven potential candidate cell-lines.  The 
cDNAs expressed in these cell-lines were purified, sequenced, and cloned.  Since each  
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Fig.1. NIH 3T3 cells are poorly susceptible to HTLV-1 Env infection.  293T and NIH 
3T3 cells were infected with HIV-luc particles, pseudotyped with the HTLV-1 Env, the 
A-MLV Env, or VSVg.  Forty-eight hours post-infection the cells were lysed and 
subjected to a luciferase assay.  Background activity (non-infected cells) was subtracted.  
Student’s t tests were performed to determine significant differences between samples 
(**, P < 0.01). 
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cell-line only expressed one cDNA, this resulted in seven candidate clones, representing 
the following cDNAs: hemoglobin alpha 1/2, gelsolin (clones 1 and 2), ribosomal protein 
L13a, structural maintenance of chromosome 5 (SMC5, clones 1 and 2), and 
transmembrane protein 208 (TMEM208/HSPC171).  These candidate clones, a GLUT-1 
cDNA clone, and the empty cloning vector, pIRES2-EGFP, were stably transfected into 
NIH 3T3 cells, and the resulting cell-lines infected with HIV-luc (HTLV-1) (Fig. 2).  We 
infected the NIH3T3.GLUT-1 cells to test the effectiveness of GLUT-1 as the HTLV-1 
receptor; although GLUT-1 increased entry by 40-fold, this was nowhere near the 8000-
fold increase seen with infection of 293T cells (positive control), suggesting that GLUT-1 
may be necessary, but is not sufficient, for HTLV-1 entry.  Infection of the 
NIH3T3.pIRES-EGFP and NIH 3T3 cells served as negative controls.  Furthermore, 
though we did not see a significant increase in infectivity with any of the candidates, we 
were able to show that a complete screen of this nature could be carried out, albeit with 
optimizations.   
On our second attempt, we used a retroviral cDNA library from a cell-line known 
to be permissive to HTLV-1 infection, HeLa S3 (Jassal, Pohler, and Brighty, 2001; Li et 
al., 1996; Trejo and Ratner, 2000).  We generated retroviral cDNA library particles (Fig. 
3), infected NIH 3T3 cells, and after adding virus, selected for two weeks.  In all, we 
counted more than 320 colonies, while there were less than five colonies on the negative 
plate; 114 cell-lines were successfully expanded.  Since most of the colonies contained 
multiple plasmids, we amplified approximately 460 cDNAs from these cell lines.  Each 
cDNA was purified and subjected to sequence analysis 
 
 59 
Fig. 2.  Candidates do not cause an increase in HTLV-1 Env infection.  The candidate 
clones were infected with HIV-luc (HLTV-1) particles.  Forty-eight hours post-infection 
the cells were lysed and subjected to a luciferase assay.  293T cells were infected as a 
positive control, while 3T3 cells were infected as one of the negative controls.  Bars 3-11 
represent 3T3 cells stably transfected with the following pIRES2-EGFP plasmids: -, 
vector alone; HA, hemoglobin alpha 1/2; G1, gelsolin (clone 1); G2, gelsolin (clone 2); 
L13a, ribosomal protein L13a; SM1, SMC5 (clone 1); SM2, SMC5 (clone 2); HSP, 
HSPC171; and GLUT-1. 
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Fig. 3. Schematic representation of the retroviral cDNA library screen.  (1) The 
HeLa S3 cDNA library E. coli stock was plated on 150-mm bacterial plates (2) and 
grown overnight. The plates were scraped and DNA from each plate was prepped (3).  
The DNA from each plate was combined into a master library mixture, and this DNA, 
along with plasmids expressing VSVg and the MLV Gag-Pol (GP), were transfected into 
293T cells (4).  The resulting retroviral HeLa S3 cDNA particles were harvested 72h later 
(5), and used to infect NIH 3T3 cells (6).  The black circles represent 3T3 cells 
transduced with cDNA virus; the white circles represent non-transduced 3T3 cells.  The 
next day these 3T3 cells were transduced with the HIV-neo (HTLV-1) virus (7).  The 
black circles represent 3T3 cells transduced with cDNA that did not allow entry of the 
viral particles; the gray circles represent 3T3 cells transduced with cDNA that did allow 
entry of the viral particles; the white circles represent non-transduced 3T3 cells; the 
white/gray cells represent non-cDNA transduced 3T3 cells that allowed entry of the viral 
particles (background cells).  Forty-eight hours later the 3T3 cells were placed under 
G418 selection.  Two weeks later, the selected colonies (8) were picked off the plate and 
expanded. 
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Selecting potential candidates 
 
We prioritized candidates that could potentially act as the receptor/attachment 
factor/entry-enhancing molecule for HTLV-1 based on three factors: (1) cellular 
localization – since we are looking for factors that can bind to and/or allow entry to the 
HTLV-1 Env, we selected candidates based on whether they are present at the plasma 
membrane and/or are known receptors; (2) frequency – pulling out a factor multiple times 
inherently implies its importance; hence we also focused on ‘multiple-hit’ proteins; and 
(3) identification as a HIV-dependency factor (HDF) – three recent studies identified over 
200 host factors potentially involved in HIV-1 replication (Brass et al., 2008; Konig et 
al., 2008; Zhou et al., 2008); due to similarities between HIV-1 and HTLV-1 infectivity, 
these HDFs could also be important in HTLV-1 replication.  However, some of the HDFs 
chosen were not the exact factors pulled out of the screens, but belonged to the same 
family of proteins (e.g. F-box/WD repeat-containing protein 11, FBXW11, was pulled 
out of one of the HDF screens, whereas we pulled out FBXW5).  Based on these criteria, 
we selected 20 potential candidates, of which 12 are membrane proteins, including 
flotillin-1 (FLOT-1) and killer cell lectin-like receptor subfamily K, member 1 
(KLRK1/NKG2D/CD314), 11 are multiple hits, including peroxiredoxin-1 (PrdX1) and 
phosphatidylinositol glycan anchor biosynthesis, class T (PIGT), and 7 are HDFs or 
HDF-related, including CD68 and Ras-related protein, Rab3D (Table 1). 
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Table 1 List of prioritized receptor candidates 
 
Receptor Candidate 
 
MPa MH (#)b 
 
HDFc 
Guanine nucleotide-binding protein subunit beta-2-like 1 (GNB2L1)   (5)  
Peroxiredoxin-1 (PrdX1)   (10)  
Phosphatidylinositol glycan anchor biosynthesis, class T (PIGT)   (13)  
Killer cell lectin-like receptor subfamily K, member 1 (KLRK1)    
HLA-A, -B, and -C (Major Histocompatibility Complex I)    
HLA-DRB1 (Major Histocompatibility Complex II)    
Flotillin-1 (FLOT-1)   (2)  
CD68   (3)  
Solute carrier family 16, member 3 (SLC16A3)    
Solute carrier family 38, member 5 (SLC38A5)   (2)  
Ras-related protein Rab3D   (2)  
Ligatin (LGTN)    
Transmembrane BAX inhibitor motif containing 6 (TMBIM6)   (3)  
Transmembrane emp24 domain-containing protein 10 (TMED10)   (2)  
Transmembrane 4 L6 family member 1 (TM4SF1)    
Protease, serine 21 (PRSS21)    
Transmembrane and coiled-coil domain-containing 1 (TMCO1)   (3)  
Yip1 domain family member 3 (YIPF3)    
Ankyrin repeat domain protein 16 (ANKRD16)    
F-box/WD repeat containing protein 5 (FBXW5)   (2)  
a MP - membrane protein 
b MH (#) - multiple hit (number of hits) 
c HDF - HIV-dependency factors identified in Brass et al. (2008), König et al. (2008), and Zhou et 
al. (2008) 
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DISCUSSION 
 
Viral tropism is an important factor to consider with viral entry/infection.  It refers 
to the specificity of a virus for cell types that are capable of producing viral progeny or 
maintaining this production potential with dormant viruses (Manel et al., 2005).  This 
tropism is determined largely by the binding of viral envelope glycoproteins to specific 
cell surface receptor(s).  However, viral and/or cellular factors and post-binding events 
that influence the completion of the viral replication cycle can impact tropism 
significantly.  Classic examples of this were revealed with the T-cell tropic strain of the 
mammalian feline leukemia retrovirus (FeLV-T) (Anderson et al., 2000), and HIV-1 
(Bieniasz et al., 1998).  For HTLV-1 infection, it seems likely that its preferential 
detection in CD4+ T cells in vivo is not due solely to Env-receptor interactions, but rather 
to a series of post-entry selection steps (Manel et al., 2005). 
In the past, three experimental approaches have been used to uncover the HTLV-1 
receptor (Manel et al., 2005): (1) infection with retroviral or non-retroviral particles 
pseudotyped with HTLV-1 Env (Clapham, Nagy, and Weiss, 1984; Manel et al., 2003; 
Sommerfelt and Weiss, 1990; Sommerfelt et al., 1988; Sutton and Littman, 1996; Trejo 
and Ratner, 2000); (2) HTLV-1 Env mediated cell-to-cell fusion (Denesvre et al., 1995; 
Hildreth, Subramanium, and Hampton, 1997; Hoshino et al., 1983; Tajima, Tashiro, and 
Camerini, 1997); and (3) binding of HTLV-1 Env to permissive cells (Gavalchin et al., 
1993; Jassal, Pohler, and Brighty, 2001; Kim et al., 2004; Manel et al., 2003).  Although 
these approaches have yielded a vast array of data, and significantly increased our 
knowledge of HTLV-1 entry/infection, they have been unable to definitively pinpoint the 
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receptor.  Our approach was designed to systematically scan the genome of a permissive 
cell-line and identify factors that enhance entry mediated by the HTLV-1 Env.  We 
isolated a total of 460 cDNAs, of which 20 were of particular interest as they fulfilled our 
prioritization criteria.  These 20 candidates fall under three broad categories – (1) 
receptor or receptor-like factors found at the plasma membrane, (2) non-receptor-like 
factors found at the plasma membrane, or (3) factors not found at the plasma membrane. 
In the first category we would include factors such as KLRK-1/NKG2D, the 
human leukocyte antigen-A, -B, -C, and -DR beta 1 (HLA-A, -B, -C, -DRB1), CD68, and 
the two solute carriers, solute carrier family 16, member 3 and solute carrier family 38, 
member 5 (SLC16A3, SLC38A5).  All are expressed at the plasma membrane of a subset 
of hematopoietic cells (Banerjee, Feuer, and Barker, 2007; Bauer et al., 1999; Lanier, 
2005; Micklem et al., 1989; Parwaresch et al., 1986; Raulet, 2003).  In addition, a number 
of these factors (HLA-A, -B, -C, CD68, and SLC38A5) were identified as HDFs/HDF-
related, and CD68 and SLC38A5 were isolated multiple times in our screen, lending 
further support to their possible role in enhancing HTLV-1 infectivity.  
In the second category we would include factors such as FLOT-1, ligatin (LGTN), 
transmembrane 4 L6 family member 1 (TM4SF1), protease, serine 21 (PRSS21), and 
Yip1 domain family member 3 (YIPF3).  These factors are all localized at the plasma 
membrane (de Gassart et al., 2003; Dermine et al., 2001; Jakoi and Marchase, 1979; 
Jakoi, Zampighi, and Robertson, 1976; Lekishvili et al., 2008; Prost et al., 2002; 
Stuermer et al., 2001), but are not known to have classic receptor-like functions.  Due to 
their localization, it is possible that these molecules somehow act as attachment factors 
and/or are involved in receptor signaling.  FLOT-1, which was isolated multiple times in 
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our screen, has been shown to be associated with lipid rafts (Lang et al., 1998; Schulte et 
al., 1997; Stuermer et al., 2001), TM4SF1 is in the family of tetraspanins, which have 
been shown to be loosely localized to lipid rafts (Berditchevski, 2001), and the murine 
form of PRSS21, TESP5, has been shown to be associated with lipid rafts (Honda et al., 
2002).  Lipid rafts are microdomains of the plasma membrane, rich in cholesterol and 
glycosphingolipids (Brown and London, 2000).  Since cholesterol has been shown to be 
important in the uptake of a number of viruses, including HTLV-1 and HIV-1 (Carter et 
al., 2009; Wielgosz et al., 2005), lipid rafts have become an important factor in viral 
entry.  Furthermore, FLOT-1 and LGTN have both been shown to lack transmembrane 
domains; instead, they are anchored to the plasma membrane by post-translational fatty 
acylation modifications, specifically palmitolyation (Gkantiragas et al., 2001; Jakoi et al., 
1987; Morrow et al., 2002).  It is interesting to note that many palmitoylated proteins are 
associated with lipid rafts, and this association has been shown to be important in T cell 
signaling (Resh, 1999). 
The factors in the third category are not known to reside at the plasma membrane, 
but could possibly be involved in enhancing HTLV-1 entry and/or infectivity indirectly.  
Of these, guanine nucleotide-binding protein subunit beta-2-like 1 (GNB2L1), PrdX1, 
PIGT, Rab3D, transmembrane BAX inhibitor motif containing 6 (TMBIM6), 
transmembrane emp24 domain-containing protein 10 (TMED10), transmembrane and 
coiled-coil domain-containing 1 (TMCO1), and FBXW5 were identified multiple times 
in our screen, while Rab3D, TMED10, ankyrin repeat domain protein 16 (ANKRD16), 
and FBXW5 were identified as HDFs/HDF-related.  Though they are not directly linked 
to the plasma membrane, Rab3D and TMED10 are known to translocate to the plasma 
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membrane (Blum et al., 1996; Millar et al., 2002; Tuvim et al., 1999), while GNB2L1 has 
been shown to loosely co-localize with clathrin (Gallina, Rossi, and Milanesi, 2001).  
PrdX1 and FBXW5 have been shown to be important in receptor signaling and signal 
transduction (Kang et al., 1998; Kang et al., 2005; Minoda et al., 2009), and PIGT, which 
is a type I transmembrane protein, has been shown to be critical for the formation of the 
glycosylphosphatidylinositol (GPI) transamidase complex and essential for attachment of 
GPI to proteins (Ohishi, Inoue, and Kinoshita, 2001). 
Due to our prioritization scheme and categorization of the 20 factors, we are 
confident that we have a strong subset of candidate proteins.  However, due to the design 
of our screen, a few possible caveats must be addressed.  Firstly, since we infected the 
NIH 3T3 cells with the retroviral cDNA library at an MOI of 1.5, we would expect, and 
did find, multiple cDNAs in all the clones isolated after the selection process.  Due to this 
fact, there is a possibility that the entry of the HTLV-1 Env was due to the expression of 
multiple cDNAs in the clones, rather than just one cDNA.  Secondly, since we are 
pseudotyping a HIV-based vector with the HTLV-1 Env, it is possible that some of the 
cDNAs we isolated were identified because they alleviated a post-entry block to HIV, 
rather than enhanced entry of HTLV-1 Env.  Thirdly, if HTLV-1 interacts with multiple 
distinct receptors/attachment factors, our screen may not pick up factors involved in 
enhancing entry, since the other, possibly crucial molecules might not be expressed.  
Despite these possible drawbacks, we have designed a unique way of searching for the 
HTLV-1 receptor(s)/attachment factor(s), and through a focused search uncovered many 
potential new candidates. 
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FUTURE DIRECTIONS 
 
The next step in our screen is to clone and re-test the 20 candidate factors we 
selected.  The clones will initially be stably transfected into NIH 3T3 cells.  These stable 
candidate cell-lines will be infected with HTLV-1 Env pseudotyped HIV-luc particles, 
and luciferase assays carried out to determine the level of entry, based on luciferase 
activity.  Any candidate cDNAs that increase luciferase activity significantly above 
background levels, to be determined empirically, will then be further tested by fusion 
assays, to determine if they cause an increase in HTLV-1 Env fusion, and knockdown 
studies, to determine if expression of the candidate in permissive cell-lines is necessary 
for HTLV-1 Env infection.  It will also be interesting to determine whether any identified 
candidate factor(s) interacts with any of the factors currently thought to increase HTLV-1 
entry, i.e. GLUT-1, NRP-1, and/or HSPGs.    
 
MATERIALS AND METHODS 
 
Retroviral cDNA library screens 
 
For the first screen, we purchased the ViraPort VSV-G Retroviral Supernatant 
Human Substantia Nigra cDNA library from Stratagene, which had a titer of 2 x 106 
infectious particles/mL.  We infected one plate with 2 x 106 NIH 3T3 cells (MOI = 1.0), 
while another, with a duplicate number of cells, was not infected (this was designated the 
‘negative’ plate, and was used to calculate our background).  Twenty-four hours later, the 
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cDNA particles were washed off the NIH 3T3 cells, and both these cells and the cells on 
the ‘negative’ plate were infected with HIV-neo (HTLV-1) particles (MOI = 5.0).  These 
HTLV-1 Env pseudotyped particles (selection virus) were generated by transfecting 293T 
cells with the pHTE-1 and pNL4-3SV40Neo+Env- plasmids. Forty-eight hours later, the 
selection virus was washed off the plates, and fresh media supplemented with G418 was 
added to the cells.  Fresh G418-supplemented media was added every three days, for the 
next three weeks, by which time individual colonies had formed.  We picked colonies 
from both the cDNA-infected and negative plates into 24-well plates, from where they 
were expanded.  We simultaneously plated cells for infection with HIV-luc (HTLV-1).  
Plasmid DNA was isolated from the candidate cell-lines and subjected to PCR (using 
primers provided with the ViraPort library) to amplify the cDNAs they harbored.  These 
cDNAs were sequenced and then identified by running the sequences through the Basic 
Local Alignment Search Tool (BLAST). 
For the second screen, we purchased the ViraPort XR HeLa S3 cDNA library 
(E. coli glycerol stock) from Stratagene, in which the cDNA plasmid library is cloned 
into pFB, a replication-defective retroviral (MMLV-based) vector.  After titering the E. 
coli glycerol stock (2 x 106 cfu/mL), we plated one hundred 150-mm LB-ampicillin agar 
plates (2 x 104 cfu/plate), and incubated them at 30°C for 24 hours (Fig. 3).  We 
harvested the colonies by scraping each plate into a small pool of LB medium.  Each of 
these 100 pools was subjected to alkaline lysis using the PureYield Plasmid Midiprep 
System (Promega), to generate cDNA library plasmid DNA.  We created a master pool of 
cDNA plasmids by combining DNA from each of the 100 individual pools.  We 
transfected 293T cells with the master pool, a VSVg expression plasmid, and a MLV 
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Gag-Pol expression plasmid, and 72 hours later harvested the retroviral cDNA library 
particles, representing the 2 x 106 distinct cDNAs.  These virus particles were used to 
infect 3 x 106 NIH 3T3 cells (MOI = 1.5).  Another plate with a duplicate number of NIH 
3T3 cells was not infected with the cDNA particles; this was designated the ‘negative’ 
plate, and was used to calculate our background.  Twenty-four hours later, the cDNA 
particles were washed off the NIH 3T3 cells, and both these cells and the cells on the 
‘negative’ plate were infected with HIV-neo (HTLV-1) particles (MOI > 10).  Forty-eight 
hours later, the selection virus was washed off the plates, and fresh media supplemented 
with G418 was added to the cells.  Fresh G418-supplemented media was added every 
three days, for the next two weeks, by which time individual colonies had formed.  We 
picked these colonies from the plate, and into 24-well plates, from where they were 
expanded.  Plasmid DNA was isolated from these colonies and subjected to PCR to 
amplify the cDNAs they harbored.  These cDNAs were sequenced and then identified by 
running the sequences through the Basic Local Alignment Search Tool (BLAST). 
 
Cells 
 
293T and NIH 3T3 cells were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM), supplemented with 10% FetalClone III (FCIII) serum, 2mM ʟ-glutamine, 
1mM sodium pyruvate, penicillin (100 U/mL), and streptomycin (100µg/mL).  After 
addition of the HTLV-1 Env pseudotyped selection virus and after transfection with the 
candidate clones, NIH 3T3 cells were selected in complete DMEM with 850ug/mL G418 
(Mediatech) for two-three weeks.     
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Plasmids, viruses, transfections, infections and luciferase assays 
 
Five million 293T cells were transfected with the HeLa S3 cDNA library plasmids 
(described above), pHCMVg (VSVg expression plasmid), and pVPack-GP (MLV Gag-
Pol expression plasmid, Stratagene) to generate the retroviral HeLa S3 cDNA virus.  Five 
million 293T cells were transfected with pHTE-1 (HTLV-1 Env expression plasmid) and 
pNL4-3SV40Neo+Env- (envelope-deficient HIV plasmid, carrying the neo resistance 
gene under the control of the SV40 promoter) to generate the HTLV-1 Env pseudotyped 
selection virus, HIV-neo (HTLV-1).  Five million 293T cells were transfected with 
pHTE, SV-A-MLV-env (amphotropic MLV Env expression plasmid), or pHCMVg and 
pNL4-3SV40Luc+Env- (envelope-deficient HIV plasmid, carrying the luciferase reporter 
gene under the control of the SV40 promoter) to generate the pseudotyped reporter 
viruses, HIV-luc (HTLV-1), HIV-luc (A-MLV), and HIV-luc (VSVg), respectively.  The 
pHCMVg, pHTE-1, pNL4-3SV40Luc+Env-, and SV-A-MLV-env plasmids have been 
described previously (Landau, Page, and Littman, 1991; Trejo and Ratner, 2000).  The 
pNL4-3SV40Neo+Env- plasmid was generated by MM Wielgosz in our laboratory.  To 
generate the candidate clones, the candidate cDNAs were cloned into the EcoRI and SalI 
sites of the pIRES2-EGFP plasmid (Clontech).  Two million NIH 3T3 cells were stably 
transfected with the candidate clones.  All transfections were carried out using TransIT-
LT1 Transfection Reagent (Mirus) as per the manufacturer’s recommendations.  One 
million cDNA-infected NIH 3T3 cells or candidate-clone-transfected NIH 3T3 cells were 
infected with HIV-luc (HTLV-1). Forty-eight hours post-infection, the cell pellets were 
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lysed in lysis buffer, and subjected to a luciferase assay (Lucifease Assay System, 
Promega). 
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Abstract 
Human T-cell leukemia virus type 1 (HTLV-1) basic leucine zipper factor (HBZ) 
is transcribed from the antisense genomic DNA strand and functions differently in its 
RNA and protein forms.  To distinguish between the roles of hbz mRNA and HBZ 
protein, we generated mutants in a proviral clone that specifically disrupt the hbz gene 
product. A proviral clone with a splice acceptor mutation that disrupts expression of the 
predominant hbz mRNA resulted in lower levels of tax mRNA.  Heterologous hbz 
expression restored Tax activity in cells expressing this mutant clone.  In contrast, 
proviral mutants that disrupt HBZ protein did not affect levels of tax mRNA.  Expression 
of hbz resulted in lower levels of p30II mRNA. Mutation of p30II overcame the effects of 
the splice acceptor mutation of hbz, and restored tax expression. Thus, there is a complex 
interplay of viral regulatory proteins controlling levels of HTLV-1 gene expression.  
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Introduction 
Human T-cell leukemia virus type 1 (HTLV-1) is a complex retrovirus belonging 
to the delta retrovirus family.  It is the etiologic agent of adult T cell leukemia lymphoma 
(ATLL) (Hinuma et al., 1981; Poiesz et al., 1980), a malignancy of CD4+ T lymphocytes, 
and a chronic neurological disorder termed HTLV-1-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP).  In addition to the gag, env, and pol genes encoding 
structural and enzymatic proteins common to all retroviruses, the HTLV-1 genome 
includes several accessory proteins, which facilitate virus transmission in vivo by 
establishing persistent infection (Collins et al., 1998; Hiraragi et al., 2006; Nicot et al., 
2004; Silverman et al., 2004; Ye et al., 2003).  The tax gene product is a potent activator 
of viral transcription (Boxus and Willems, 2009; Felber et al., 1985; Yin and Gaynor, 
1996).  In addition, through its involvement in a number of cellular transcription 
pathways, Tax stimulates the proliferation, survival, and transformation of HTLV-1-
infected T cells (Boxus and Willems, 2009; Matsuoka and Jeang, 2007; Peloponese, 
Kinjo, and Jeang, 2007).  Another regulatory protein, p30II, down-regulates Tax 
expression by interaction with, and nuclear retention of tax mRNA (Nicot et al., 2004).  
Other HTLV-1 regulatory proteins include Rex, p12I, p27I, and p13II (Fig. 1) (Albrecht 
and Lairmore, 2002). 
Recently, another HTLV-1 regulatory gene was identified on the antisense 
genomic DNA strand; since its protein product includes a basic region and a leucine 
zipper, it was designated HTLV-1 bZIP factor, or HBZ (Cavanagh et al., 2006; Gaudray 
et al., 2002; Larocca et al., 1989).  The hbz mRNA is expressed in primary ATLL cells, 
despite repression of other viral transcripts (Matsuoka and Green, 2009; Satou et al., 
 91 
2006).  Multiple hbz mRNA initiation sites have been identified in the 3′-LTR (Cavanagh 
et al., 2006; Yoshida et al., 2008), which result in three transcripts; two are spliced (hbz 
SP1 and SP2) while the other is unspliced (hbz US) (Fig. 1) (Cavanagh et al., 2006; 
Murata et al., 2006; Satou et al., 2006).  The SP1 spliced variant is the most abundant 
form in ATLL cell lines and infected lymphocytes from ATLL patients (Satou et al., 
2006; Usui et al., 2008).  The promoters for hbz SP1 and hbz US have been identified, 
and studies suggest that the levels of antisense transcription are 20-50 fold lower (Arnold 
et al., 2006; Larocca et al., 1989) than sense transcription (Yoshida et al., 2008).  The hbz 
SP1 and hbz US mRNAs encode protein products that differ only in their N-terminal 
seven amino acids, whereas the SP2 transcript does not code for a protein product, and its 
function is undefined. The hbz transcripts include sequences complementary to the other 
HTLV-1 transcripts encoded from the sense genomic DNA strand.   
HBZ has been reported to be a negative modulator of Tax.  Upon exogenous over-
expression, HBZ binds to and inhibits CREB-2, an essential transcription factor for Tax-
mediated trans-activation of the viral promoter (Basbous et al., 2003; Gaudray et al., 
2002).  However, HBZ expression does not affect the ability of HTLV-1 to immortalize T 
lymphocytes in culture (Arnold et al., 2006); in fact, HBZ enhances virus infectivity and 
persistence in vivo. Another study identified a distinct activity of hbz mRNA, and 
demonstrated enhanced T cell proliferation in culture and transgenic mice (Satou et al., 
2006).  They identified a domain of hbz mRNA, localized to the first stem-loop (SL), that 
mediated this activity. These data led to the hypothesis that the hbz gene has dual 
functionality:  hbz mRNA promotes T-cell proliferation, while HBZ protein suppresses 
Tax-mediated viral transcription. 
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 In order to delineate and differentiate the activities of hbz mRNA and HBZ 
protein, we used an infectious molecular proviral clone of HTLV-1 (Kimata et al., 1994) 
to assess mutations  that specifically affect the structure and/or expression of the hbz gene 
product.  This led to the unexpected identification of a third activity of hbz that promotes 
tax mRNA expression.  These results have important implications for understanding the 
regulation of HTLV-1 gene expression. 
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Results 
Construction and characterization of pACH.HBZ mutant proviral clones 
To investigate the role of HBZ in the context of an HTLV-1 provirus, we 
generated four HBZ mutant proviral clones (Fig. 2A).  For this purpose, we used a well 
characterized infectious molecular clone, designated pACH (Kimata et al., 1994).  
pACH.HBZ-∆SA has a mutation in the splice acceptor site of the hbz gene that prevents 
the proper splicing of the SP1 and SP2 hbz mRNAs (Fig. 1).  pACH.HBZ-KO is a 
knockout mutant that terminates the predominant HBZ protein derived from the SP1 
variant at amino acid seven, as well as the HBZ protein derived from the US variant at 
amino acid 10 (Fig. 2A).  pACH.HBZ-TRUN is a truncation mutant that deletes the 
leucine zipper portion of the bZIP domain of variants SP1 and US, through insertion of a 
termination codon in place of codon 158 (SP1)/codon 161 (US) within the 206 (SP1)/209 
(US) amino acid open reading frame.  The leucine zipper portion of HBZ is required for 
the association of HBZ with CREB-2, JunB, and c-Jun (Basbous et al., 2003; Gaudray et 
al., 2002).  pACH.HBZ-SL has a mutation that disrupts the stem-loop at the 5′ end of the 
hbz mRNA that is only found in the SP1 variant (Satou et al., 2006).  Although mutants 
similar to pACH.HBZ-KO and pACH.HBZ-TRUN were constructed and tested by other 
investigators (Arnold et al., 2006), our studies were aimed at distinguishing the role of 
hbz mRNA versus HBZ protein at physiological levels. 
We first determined the levels of hbz SP1 RNA expressed from the proviral 
mutant plasmids (Fig. 2B).  293T cells were transiently transfected with each of the 
various mutants, and total RNA isolated from these cells was subjected to real-time RT-
PCR, using primers that spanned the hbz splice junction (Fig. 1).  The results from an 
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average of at least three independent experiments are shown in Fig. 2B.  Mutating the 
splice acceptor site of the hbz gene significantly reduced the steady state levels of hbz 
SP1 RNA by greater than 90% (P = 0.03).  As expected, mutants pACH.HBZ-KO and 
pACH.HBZ-TRUN, which were constructed to truncate the HBZ protein without 
affecting hbz mRNA, were found to have no significant effects on the levels of hbz RNA 
(pACH.HBZ-KO: P = 0.57; pACH.HBZ-TRUN: P = 0.15).  Disrupting the stem-loop 
structure of hbz mRNA did not affect the stability of the hbz mRNA, since steady state 
levels were equivalent to those of cells expressing pACH.HBZ-WT (P = 0.35).  We also 
measured levels of total hbz RNA in cells transfected with the pACH.HBZ-WT and 
pACH.HBZ-∆SA plasmids (Fig. 2B, inset), and found that the levels were decreased by 
69% in the presence of the splice acceptor mutation.  These levels of total hbz most likely 
correspond to the hbz US transcript, as this level is consistent with previously reported 
levels of hbz US (Usui et al., 2008)  
In order to examine the expression of HBZ protein from the various mutants, we 
generated HBZ wild-type (pHBZ) and mutant (pHBZ-KO, pHBZ-TRUN, and pHBZ-SL) 
expression plasmids, inserting a triple flag tag at the C-terminus of each predicted protein 
product. 293T cells were transiently transfected with these plasmids, and Western blot 
analysis was carried out (Fig. 2C). As expected, no HBZ expression was seen from cells 
transfected with the HBZ-KO mutant.  The HBZ-TRUN mutant produced a truncated 
HBZ-flag protein of 27 kDa.  Cells expressing wild-type HBZ and the HBZ-SL mutant 
both produced HBZ-flag proteins of 34 kDa.   Levels of expression of WT, TRUN, and 
SL HBZ proteins were equivalent. 
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To confirm that pACH.HBZ-∆SA does not produce an unspliced gene product, 
we generated an HBZ-∆SA expression plasmid (pNHBZ-∆SA) that contains both the 
exons of hbz SP1 and the sequence corresponding to the intronic region between them.  
293T cells were transiently transfected with this plasmid and a HBZ wild-type expression 
plasmid, pNHBZ, and Western blot analysis was carried out with anti-HBZ antiserum 
(Fig. 2D).  We did not see any HBZ expression from pNHBZ-∆SA, confirming the lack 
of an unspliced gene product.  Additionally, we did not see a difference in unspliced 
mRNA levels between cells transfected with the wild-type and ∆SA mutant proviral 
plasmids (data not shown).      
 
Loss of hbz leads to reduction in tax expression 
The pACH.HBZ mutants were used to determine the effects of hbz mRNA and 
HBZ protein on expression of other HTLV-1 genes. Total RNA isolated from 293T cells 
transiently transfected with the HBZ proviral mutants was subjected to real-time RT-PCR 
to measure the levels of tax transcript. The primers used to amplify tax spanned the 
second splice junction (Fig. 1).  The results from an average of four independent 
experiments are shown in Fig. 3A.  There was a 70% decrease in the steady state level of 
tax mRNA expressed from the pACH.HBZ-∆SA mutant, as compared to the level of tax 
mRNA expressed by pACH.HBZ transfected cells.  Jurkat cells transfected with the 
pACH.HBZ-WT plasmid expressed 0.12 ± 0.07 pg Tax mRNA, while those transfected 
with the pACH.HBZ-∆SA mutant plasmid expressed 0.0 ± 0.02 pg Tax mRNA (P = 
0.03) (data not shown).  No significant changes were seen in tax mRNA expressed from 
the other pACH mutants (Fig. 3A).  The levels of tax mRNA, relative to that of 
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pACH.HBZ-WT expressing cells, with pACH.HBZ-KO, pACH.HBZ-TRUN, and 
pACH.HBZ-SL were 87%, 104%, and 73%, respectively (P = 0.78, 0.96, and 0.51, 
respectively).   
Levels of viral proteins were also assessed, and normalized to levels of actin, used 
as a loading control (Fig. 3B).  There was a 64% decrease in the amount of Tax protein 
expressed from the pACH.HBZ-∆SA mutant, compared to Tax protein expressed from 
pACH.HBZ transfected cells.  No significant decrease in Tax protein was seen with the 
other mutants.    
Since Tax is responsible for the trans-activation of viral transcription, the levels 
of the viral structural protein, Gag were measured in the cellular lysate and virus particles 
in the culture supernatant.  As expected, levels of Gag p24 and p19 were also decreased 
in cells transfected with pACH.HBZ-∆SA compared to pACH.HBZ-WT (Fig. 3B, lane 
3), as well as in virus particles released into the supernatant from those cells (Fig. 3C, 
lane 3).  These results suggest that the effect of hbz mRNA on the levels of tax mRNA 
also influences the levels of Gag expression in transfected cells and the levels of released 
virus particles. 
 
Trans-complementation of hbz increases Tax activity in pACH.HBZ-∆SA cells to 
wild-type levels 
To ensure that the effects on steady state levels of Tax in pACH.HBZ-∆SA 
transfected cells were due to loss of hbz mRNA, we measured levels of Tax-mediated 
LTR gene expression in the presence of increasing amounts of hbz.  Co-transfection of 
pACH.HBZ-WT or pACH.HBZ-∆SA, as a source of Tax, together with an LTR-
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luciferase reporter plasmid, provided a sensitive quantitative measure of Tax activity.  It 
has previously been shown that Tax expressed from the pACH plasmid is able to trans-
activate the HTLV-1 LTR (Robek and Ratner, 1999).  In this study, the specific role of 
Tax in transcriptional transactivation was confirmed using the M47 Tax mutation in 
pACH, a mutation which prevents Tax from upregulating transcription through 
CREB/ATF (Smith and Greene, 1990).  This mutant had 50-fold lower levels of HTLV-1 
LTR activation, using the LTR-luciferase reporter plasmid, compared to wild-type 
pACH.   
In the trans-complementation experiment with hbz, increasing quantities of a 
plasmid were utilized in which hbz was expressed under the regulation of a CMV 
promoter, pHBZ (Fig. 4A).  In cells transfected with pACH.HBZ-∆SA, together with 
increasing amounts of the hbz expression plasmid, the levels of LTR-directed gene 
expression increased.  It should be noted that in the presence of 4µg pHBZ, the level of 
Tax activity in pACH.HBZ-∆SA transfected cells increased to levels seen in 
pACH.HBZ-WT transfected cells.  The levels of Tax activity also increased in cells 
transfected with pACH.HBZ-WT in the presence of pHBZ.  However, there was no 
significant increase in Tax activity with increasing amounts of pHBZ in cells transfected 
with a Tax expression plasmid (CMV-Tax).  One explanation for this result is that 
another viral gene, expressed from the proviral plasmid, is required for the effect of hbz 
on tax expression. 
As in the previous experiment (Fig. 3), we examined the levels of Gag protein in 
the cellular lysate and viral supernatant, as a further measure of Tax activity. As 
expected, the levels of Gag p24 in the lysate increased in the presence of exogenous hbz 
 98 
(Fig. 4B, lanes 4 and 6, compared to lanes 3 and 5, respectively), and significantly more 
viral particles were released into the supernatant (Fig. 4C, lanes 4 and 6, compared to 
lanes 3 and 5, respectively).  
 
hbz represses p30II to indirectly promote tax expression 
The HTLV-1 accessory protein p30II is a nuclear protein that retains the doubly 
spliced tax mRNA in the nucleus, leading to a reduction in the amount of Tax protein 
(Nicot et al., 2004).  Since p30II is a negative regulator of tax, we hypothesized that hbz 
may negatively regulate p30II in order to promote tax mRNA expression. Since hbz 
mRNA is transcribed from the (-) strand of the HTLV-1 provirus, it is a natural antisense 
RNA to genes expressed from the (+) proviral DNA strand.  Since the majority of the hbz 
transcript overlaps the p30II transcript, we hypothesized that the hbz mRNA binds to the 
p30II mRNA to promote its degradation or inhibit its translation. 
To test our hypothesis, we co-transfected 293T cells with pMHp30IIHA1, a p30II 
expression plasmid and pHBZ, and carried out real-time RT-PCR on total RNA from the 
cells (Fig. 5A).  In the presence of increasing amounts of HBZ, we saw a significant 
decrease in the levels of p30II mRNA.  To determine whether this effect was dependent 
on HBZ protein or hbz mRNA, we generated a protein mutant of pHBZ, pmHBZ, 
mutating the initiator ATG to TTG.  In the presence of increasing amounts of mutant 
pHBZ, we also found a significant decrease in the levels of p30II mRNA, suggesting that 
the hbz mRNA, not the HBZ protein, is responsible for inhibiting levels of p30II mRNA.  
The p30II protein levels are also reduced in the presence of the wild-type and mutant 
pHBZ (Fig. 5B), confirming that hbz mRNA inhibits synthesis of p30II protein. 
 99 
To investigate the role of p30II, we generated two p30II mutant proviral clones.  
Both pACH∆p30 and pACH.HBZ-∆SA∆p30 include a termination codon in place of 
amino acid eight of the p30II open reading frame, in the context of the hbz wild-type and 
hbz splice-deficient expression plasmids, respectively (Fig. 1).  293T cells were 
transiently transfected with these plasmids and the cellular lysate and supernatant 
evaluated for levels of Gag (p24 and p19) protein.  In the absence of p30II, there was a 
1.95-fold increase in the levels of Gag protein in the cellular lysate (Fig. 5C, lane 3, 
compared to lane 2) and a four-fold increase over wild-type in the viral supernatant (Fig. 
5D, lane 3, compared to lane 2), which corresponds, as expected, to an increase in the 
level of Tax protein.  As seen previously (Fig. 3), loss of hbz leads to a decrease in the 
amount of Gag protein in the cellular lysate and supernatant (Fig. 5C and 5D, lane 4).  
However, the loss of hbz was overcome by deleting p30II, as evidenced by an increase in 
the levels of Gag protein in the cellular lysate (Fig. 5C, lane 5) and viral supernatant (Fig. 
5D, lane 5) from cells transfected with pACH.HBZ-∆SA∆p30.  Taken together, these 
results suggest that hbz promotes expression of tax indirectly through p30II. 
 
Discussion 
Since the discovery of the HTLV-1 antisense hbz gene (Gaudray et al., 2002), 
numerous studies have been carried out to establish its role in HTLV-1 replication and 
pathogenesis.  Though these studies have been informative and have established a 
foundation for hbz in the HTLV-1 field, the function of hbz in vivo is still unclear.  HBZ 
was identified as a binding partner to CREB-2; it binds CREB-2 through its basic leucine 
zipper (bZIP) domain (Gaudray et al., 2002).  Since CREB-2 has been shown to 
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cooperate with Tax in trans-activating the HTLV-1 LTR (Ching et al., 2004), studies 
have shown that exogenously over-expressed HBZ protein down-regulated Tax-mediated 
viral transcription by binding CREB-2 (Gaudray et al., 2002; Lemasson et al., 2007).  
Furthermore, Tax has been shown to activate a number of cellular pathways, such as the 
activator protein-1 (AP-1) pathway (Fujii et al., 1991; Fujii, Sassone-Corsi, and Verma, 
1988; Hooper et al., 1991).  Studies with exogenous HBZ showed that, through its bZIP 
domain, HBZ could bind to members of the AP-1 pathway (cJun and JunB) and down-
regulate Tax-mediated AP-1 transcription (Basbous et al., 2003; Clerc et al., 2009; Hivin 
et al., 2007; Matsumoto et al., 2005).  However, since these studies employed over-
expression of HBZ in the absence of other viral proteins, a more physiologically relevant 
study was carried out using HBZ expressed from a molecular clone of HTLV-I (Arnold et 
al., 2006).  Data from this study showed that HBZ protein enhanced viral infectivity and 
persistence in vivo.  In addition to this function of HBZ protein, the hbz mRNA has been 
shown to promote T-cell proliferation (Arnold et al., 2008; Satou et al., 2006).   
Since previous studies suggested that hbz has dual functionality, we examined the 
effects of various proviral hbz mRNA and protein mutants on viral gene expression.  We 
showed that a loss of hbz mRNA leads to a significant reduction in the levels of tax 
mRNA (Fig. 3).  This reduction of tax mRNA leads, as expected, to lower Tax protein 
levels, and a reduction in the levels of Gag protein and virus particle production.  These 
data are in contrast to previous work that showed that hbz-specific short hairpin (sh)-
RNAs, which down-regulated the levels of hbz in an HTLV-1 T-cell line, did not affect 
levels of gag/pol and tax/rex mRNAs or p19 Gag and Tax protein (Arnold et al., 2008).  
A possible reason for this discrepancy is discussed below.    
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To confirm that the reduction in Tax levels was a consequence of the loss of hbz 
mRNA, a complementation study was carried out in which increasing amounts of 
exogenous hbz were expressed.  In contrast to previous work (Arnold et al., 2006), we 
found that when Tax was expressed from a proviral plasmid, the levels of Tax activity 
increased with increasing amounts of pHBZ (Fig. 4).  Of particular note is that, in the 
presence of 4ug of pHBZ, Tax activity in cells transfected with the splice-deficient hbz 
mutant increased to wild-type levels.   
Another interesting finding was that when Tax was expressed from an expression 
plasmid rather than a proviral expression plasmid, there was no increase in Tax activity in 
the presence of pHBZ (Fig. 4).  We concluded that a viral gene, expressed from the 
proviral plasmid, was required for hbz to have its effect on tax.  Possible explanations for 
this result are: (1) hbz represses an inhibitor of tax or (2) hbz promotes an activator of tax.  
For two reasons, the first hypothesis is more attractive.  First, since hbz is transcribed 
from the (-) strand of the HTLV-1 proviral genome, it is a natural antisense RNA to other 
viral transcripts; it could form a double stranded (ds)-RNA structure with other viral 
transcripts, which may be degraded by cellular nucleases or merely inhibit their 
translation.  Second, it is notable that another HTLV-1 gene encoding p30II, has a 
repressive function on tax (Nicot et al., 2004), similar to that manifested by loss of hbz.  
The p30II protein retains doubly spliced tax mRNA in the nucleus, thereby decreasing the 
levels of Tax protein.  It is notable that the hbz transcript overlaps those encoding pX 
open reading frames I and II, which encode p12I and p30II and p13II, respectively (Fig. 1).  
Of the three accessory proteins encoded by these regions of the viral genome, only p30II 
has been shown to directly regulate tax expression (Albrecht and Lairmore, 2002).  
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Hence, we hypothesized that hbz inhibits p30II mRNA, and the reduction in p30II protein 
expression leads to an increase in the levels of Tax protein.  Moreover, steady state levels 
of p30II mRNA are low compared to the level of hbz mRNA, in contrast to levels of tax 
and gag mRNAs, thus p30II mRNA would be predicted to be exquisitely sensitive to 
inhibition by a complementary RNA sequence.    
The discrepancy between the currently reported studies and those reported 
previously based on studies of the effects of shRNAs to hbz (Arnold et al., 2008), can be 
explained by the fact that the expression of p30II may have been suppressed in the 
transformed cell lines used in the previous study.  Furthermore, it is unclear whether the 
shRNAs were able to reduce the levels of hbz RNA effectively enough to repress its 
effect on p30II.  Another difference between the current study with an infectious proviral 
clone and the previous study using transformed cell lines may be related to differences in 
levels of hbz mRNA and its mechanism of gene expression.  It is unclear whether hbz 
expression in transformed cell lines is derived predominantly from intact proviruses or 
deleted proviruses (Matsuoka and Green, 2009).  Expression of hbz mRNA from a 
deleted provirus in ATLL cell lines may repress tax expression from intact proviruses in 
the same cell, which may resemble the results in the current study in which trans-
complementation effects of hbz were examined (Fig. 4).  Although (+) strand 
transcriptional occlusion of the hbz promoters in an intact provirus may inhibit its 
expression, we found only four-fold lower levels of hbz mRNA generated from the full 
provirus compared to that generated from the 3′ half of the provirus, under our transient 
transfection conditions (data not shown).  Thus, promoter occlusion is not likely a major 
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restrictive mechanism for hbz expression except when the 5′ LTR promoter is highly 
upregulated (Greger et al., 1998; Palmer et al., 2009). 
To examine the effect of hbz on p30II, we measured levels of p30II mRNA in the 
presence of increasing amounts of wild-type HBZ and an HBZ protein mutant.  We found 
that levels of p30II mRNA were significantly reduced in either case, implicating hbz 
mRNA for this function (Fig. 5).  Furthermore, we generated two p30II mutants in the 
context of the hbz wild-type and hbz splice-deficient mutant plasmids, to examine the 
effect of p30II on Tax activity.  We observed that in the absence of p30II, there was an 
increase in the levels of Gag proteins, and virus particle production (Fig. 5).  Further 
studies focusing on the relationship between hbz and p30II mRNA will further define the 
detailed molecular mechanism for this interaction. 
The current studies implicate hbz mRNA rather than HBZ protein in promoting 
Tax expression and activity. Mutations that disrupt the coding capacity of hbz but do not 
affect hbz mRNA, pACH.HBZ-KO and pACH.HBZ-TRUN, did not perturb Tax 
expression (Figs. 2 and 3).  It has been proposed that a stem-loop structure at the 5′-end 
of hbz mRNA is important for its growth-promoting activity (Satou et al., 2006). It is 
conceivable that this stem-loop RNA sequence may bind specific cellular proteins or is 
processed into microRNA that could inhibit other viral genes. However, in the current 
studies, pACH.HBZ-SL exhibited similar activity to pACH.HBZ-WT with respect to Tax 
expression (Fig. 3).  This suggests that the effects of hbz mRNA in promoting Tax 
expression are not specifically localized to the 5’ stem-loop structure. 
An interesting recent observation is that the spliced hbz transcript (hbz SP1) and 
the pX region are present in all ATLL cell lines, regardless of levels of tax expression 
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(Matsuoka and Green, 2009; Satou et al., 2006).  Since it is known that Tax elicits a 
strong cytotoxic T-lymphocyte (CTL) response in vivo, it is conceivable that the virus has 
evolved intricate mechanisms to regulate the levels of Tax, in order to maximize its 
spread.  It is possible that hbz and p30II work together to provide this tight regulation 
early in infection.  A possible model of how the hbz mRNA controls tax expression, via 
p30II, is shown in Fig. 6.  This model proposes that hbz mRNA down-regulates p30II 
mRNA and inhibits synthesis of the p30II protein (Fig. 6, step 1).  Thus, in the presence 
of hbz mRNA, less p30II protein is present in the nucleus (step 2) to retard tax mRNA 
nucelo-cytoplasmic transport (step 3). Consequentially, tax mRNA is more readily 
transported to the cytoplasm, and translated (step 4). Therefore, in the presence of hbz 
mRNA, there is an increased level of Tax protein and thus, increased levels of other viral 
gene products. These hypotheses, testable in animal models and clinical studies, may 
provide new insights into HTLV-1 pathogenesis. 
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Materials and Methods 
Cells 
293T cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM), 
supplemented with 10% FetalClone III (FCIII) serum (Hyclone), 2mM glutamine, 1mM 
sodium pyruvate, penicillin (100 U/mL), and streptomycin (100µg/mL). 
 
Plasmids 
 
The HTLV-1 molecular proviral clone pACH was used in this study (Kimata et al., 
1994).  Site directed mutagenesis was performed by a PCR overlap extension method 
(Higuchi, Krummel, and Saiki, 1988).  pACH.HBZ-∆SA was generated by introducing a 
T to G silent point mutation (nt. 7268), which abolishes the splice acceptor site of the hbz 
gene.  pACH.HBZ-KO was generated by introducing a G to A point mutation (nt. 7258), 
which terminates the HBZ protein at amino acid seven (HBZ SP1 open reading frame).  
This mutation also results in an arginine to glutamine change in the p30II accessory 
protein.  However, this does not affect the activity of p30II (Arnold et al., 2006).  
pACH.HBZ-TRUN was generated by introducing a C to A point mutation (nt. 6807), 
which terminates the HBZ protein at amino acid 158, and truncates the protein by 
deleting its leucine zipper domain.  pACH.HBZ-SL was generated by mutating the 
sequence 8670GGC8672 to TTT.  This change was based on a previously described mutant, 
which mutates the stem-loop structure in the hbz gene (Satou et al., 2006).  pACH∆p30 
and pACH.HBZ-∆SA∆p30 were generated by introducing a C to G point mutation (nt. 
6850) in pACH and pACH.HBZ-∆SA, respectively.  This mutation terminates the p30II 
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protein at amino acid eight.  The sequence numbers are based on that of pACH.  To 
ensure that the mutations had no effect on the integrity of the proviral plasmids, we 
digested the plasmids with the PvuII restriction enzyme, to check for any gross deletions 
in the plasmids, and sequence analysis of the plasmids was performed.  The HBZ 
expression vectors, pHBZ1 and pHBZ2, were generated by cloning the hbz SP1 cDNA 
into the SnaBI and XbaI and EcoRI and XbaI sites of p3xFLAG-CMV-14 (Sigma-
Aldrich), respectively. The mutant HBZ expression plasmids, pHBZ-KO, pHBZ-TRUN, 
and pHBZ-SL, were generated in a similar manner to pHBZ1, by cloning the mutant hbz 
SP1 cDNAs.  The modified HBZ expression vector, pNHBZ, was generated by cloning 
the hbz SP1 cDNA into the EcoRI and BamHI sites of p3xFLAG-CMV™-10 (Sigma-
Aldrich).  The pNHBZ-∆SA plasmid was generated by amplifying the sequence 
corresponding to the two hbz SP1 exons and the intronic region from pACH, and cloning 
into the same plasmid as pNHBZ.  The pmHBZ plasmid was generated by mutating the 
initiating ATG in pHBZ2 to TTG.  The pMHp30IIHA1 plasmid was a generous gift from 
Dr. C. Nicot (Nicot et al., 2004).  The LTR-luciferase (LTR-luc) reporter plasmid and the 
CMV-Tax plasmid have been described previously (Rauch et al., 2009; Smith and 
Greene, 1990). 
 
Transfections and luciferase assay 
To test the various mutants, 5 x 106 293T cells were transfected with 10ug of pACH, a 
mutant proviral plasmid, or an empty plasmid, in the presence or absence of 5ug of 
pHBZ1.  At 96h post-transfection, the cells were washed from the plate and pelleted.  The 
supernatants were filtered through 0.45µm filters (Corning) and subjected to 
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ultracentrifugation in a Beckman-Coulter L7 Ultracentrifuge.  These lysates were used 
for Western blot analysis.  The cell pellets were washed with PBS; half of the cells were 
used for real-time RT-PCR, while the other half was used for Western blot analysis.  
293T (3 x 106) cells were transfected with 5ug of pHBZ1 or pNHBZ, a mutant HBZ 
expression plasmid, or an empty plasmid.  At 48h post-transfection, the cells pellets were 
lysed and used for Western blot analysis.  293T (3 x 106) cells were transfected with 3ug 
of pMHp30IIHA1, and either 0.5ug, 2ug, or 8ug of pHBZ2 or pmHBZ, or 5ug of pHBZ2 or 
pmHBZ.  DNA levels were kept constant with empty vector.  At 48h post-transfection the 
cell pellets were lysed, and used for real-time RT-PCR, or Western blot analysis.  To test 
for Tax activity, 2.5 x 105 293T cells were transfected with 1ng LTR-luc, 1ug of 
pACH/mutant, pCMV-Tax, and 0, 2, 3, or 4ug of pHBZ.  Empty vector was included to 
equalize the amount of DNA added, where necessary.  At 48h post-transfection, the cell 
pellets were resuspended in lysis buffer and subjected to a luciferase assay (Luciferase 
Assay System, Promega).  All transfections were carried out using TransIT-LT1 
Transfection Reagent (Mirus) according to the manufacturer’s recommendations.  Five 
million Jurkat cells were transfected with 15ug of pACH.HBZ-WT or pACH.HBZ-∆SA 
proviral plasmids, using polyethylenimine (PEI) transfection reagent (Sigma-Aldrich).   
 
Quantitative real-time RT-PCR 
Total RNA was extracted from transfected 293T cells using the RNeasy kit (Qiagen).  
One microgram of RNA was subjected to reverse transcription using the SuperScript III 
First-Strand Synthesis System (Invitrogen).  Gene-specific reverse primers were used to 
generate cDNAs; the primers used were as follows: Tax (GCtaxR) – 
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7649CCATTTCGGAAGGGGGAGTATTTGC7625, hbz SP1 and total hbz (GChbzoR) – 
6857TTGTCTCCACTTGCGCTCACGGCG6880, and p30 (GChbzoF) – 
ATGGTTAACTTTGTATCTGTAGGGC.  Reactions were performed both in the 
presence and absence of reverse transcriptase to control for DNA contamination.  The 
cDNAs (3µL) were subjected to real-time PCR using a 2X iQ SYBR Green Supermix 
(Bio-Rad) and gene-specific primer pairs (500nM each), as follows: Tax (GCtaxF) – 
5117AGCTGCATGCCCAAGACCCGTCGGA5141 and GCtaxR, HBZ SP1 (GChbznF) – 
8799TCTAAGGGAGCGCCGGACAAAG8778 and GChbzoR, total HBZ (GChbztotalF) – 
AAACGCATCGTGATCGGCAGC and GChbzoR, and p30 – GChbzoR and GChbzoF.  
The amount of each transcript present was determined based on a specific standard curve 
generated from log10 dilutions of plasmids containing cloned copies of the particular 
amplified sequences.  Samples and standards were run in triplicate and the final values 
were averaged, after background values were subtracted.  
 
Western blot analysis 
Cell lysates were prepared using lysis buffer (50mM Tris-Cl, pH 6.8, 150mM NaCl, 
1mM EDTA, 1% Triton X-100) plus protease inhibitors.  Lysate (200µg) was separated 
by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to polyvinylidene fluoride (PVDF; Millipore) membranes, blocked with 5% 
dry milk in TBS-Tween (10mM Tris-Cl, pH 7.5, 150mM NaCl, 0.05% Tween-20) and 
probed overnight with 1:100 HTLV-1 positive patient serum (p19, p24), 1:25 anti-Tax 
antibody (supernatant from hybridoma cell line 168A51-42; NIH AIDS Research & 
Reference Reagent Program) (Langton et al., 1988), 1:1000 anti-Flag antibody (Sigma-
 109 
Aldrich), 1:500 anti-HBZ antiserum (a generous gift from Dr. P. L. Green), or 1:250 anti-
HA antibody (Abgent) or for 30 minutes with a horseradish peroxidase (HRP)-conjugated 
anti-actin antibody (1:2000; Santa Cruz Biotechnology, Inc.).  After washing with TBS-
Tween, the appropriate HRP-labeled secondary antibody was added (1:3000 anti-human 
antibody [Amersham], 1:5000 anti-mouse antibody [Amersham], or 1:2000 anti-rabbit 
antibody [Pierce]).  The blots were developed using SuperSignal West Femto substrate 
(Pierce) and the proteins were visualized with an Alpha Innotech imager (Model: 
ChemiImager). 
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Fig. 1. Schematic representation of the HTLV-1 genome. The viral mRNAs, their 
direction of transcription and location of the open reading frames (black boxes) are 
shown. hbz SP1 and SP2 are two spliced variants of hbz mRNA, while hbz US is the 
unspliced transcript. The dotted lines represent the introns removed after mRNA splicing. 
The arrows represent the primers used to amplify the viral mRNAs for the RT-PCR 
assays. The white cross in p30 represents the location of the p30 stop codon, introduced 
to generate the ∆p30 mutants. The black line above hbz SP1 represents the location of the 
stem-loop structure in hbz. 
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Fig. 2. Analysis of the hbz mRNA transcript and HBZ protein. (A) Schematic 
representation of wild-type HBZ (WT), with its splice donor (SD) and acceptor (SA) sites 
and bZIP domain indicated. The four HBZ mutants generated for this study are also 
depicted. These mutants were made in the context of the pACH proviral clone. ∆SA, 
splice-deficient mutant; KO, knockout mutant; TRUN, truncation mutant; SL, stem-loop 
mutant. (B) 293T cells were transfected with the pACH.HBZ-WT or mutant plasmids. 
Total RNA was isolated 96h post-transfection, and the hbz SP1 mRNA amplified by real-
time RT-PCR using primers shown in Fig. 1. Background values were subtracted and 
data normalized to WT.  GAPDH was amplified as an internal control, and did not differ 
significantly between samples. These results represent an average of at least three 
independent experiments. Inset, total hbz mRNA was amplified by real-time RT-PCR 
using the primers within exon 2 of the hbz gene shown in Fig. 1.  Background values 
were subtracted and data normalized to WT (∆SA value is 0.31).  Student’s two-tailed t 
tests were performed to determine significant differences between samples (*, P < 0.05; 
**, P < 0.01). (C) 293T cells were transfected with pHBZ1 (pHBZ) or mutant HBZ 
expression plasmids. Western blot analysis was carried out to show HBZ-flag expression 
from these plasmids, using anti-Flag antibody.  The size of the proteins are indicated to 
the right of the blot.  Detection of actin was carried out as a loading control. (D) 293T 
cells were transfected with pNHBZ or pNHBZ-∆SA expression plasmids.  Western blot 
analysis was carried out to show HBZ expression (arrow) from these plasmids, using 
anti-HBZ antibody. Detection of actin was carried out as a loading control.  The 
background bands (bkgd. bands) are indicated to the left of the blot. **, the intensity of 
this band (as compared to the others) is probably due to protein degradation.  It cannot 
 114 
represent an HBZ protein translated using an internal ATG, since there is no start site that 
would produce a protein of that size.     
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Fig. 3. HTLV-1 gene expression in the absence of hbz mRNA or HBZ protein. (A) 
293T cells were transfected with the pACH.HBZ-WT or mutant plasmids. Total RNA 
was isolated 96h post-transfection, and the tax mRNA amplified by real-time RT-PCR, 
using primers shown in Fig. 1. GAPDH was amplified as an internal control, and did not 
exhibit significant differences between samples. These results represent an average of 
four independent experiments. Student’s two-tailed t tests were performed to determine 
significant differences between samples (*, P < 0.05). (B and C) Western blot analysis 
was carried out to measure levels of Tax and Gag (p19 and p24) proteins in the (B) 
lysates and (C) viral supernatant. Detection of actin was carried out as a loading control.  
The numbers above the blots represent the lane numbers, while the numbers below the 
blots represent the densitometry signal of the bands.  A representative experiment is 
shown from a total of three experiments.  
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Fig. 4. Trans-complementation with heterologous hbz rescues the defect seen with 
the mutation of hbz in the pACH infectious clone. (A) 293T cells were co-transfected 
with LTR-luc, and with the pACH.HBZ-WT or pACH.HBZ-∆SA plasmids, or CMV-
Tax, in the presence of increasing amounts of pHBZ. Luciferase assays were carried out 
48h post-transfection. Student’s two-tailed t tests were performed to determine significant 
differences between samples (*, P < 0.05; **, P < 0.01). A representative experiment is 
shown from three total experiments. (B and C) 293T cells were transfected with the 
pACH.HBZ-WT or pACH.HBZ-∆SA plasmids in the presence or absence of pHBZ. At 
96h post-transfection Western blot analysis was carried out to measure levels of Gag (p19 
and p24) proteins in the (B) lysates and (C) viral supernatant. Detection of actin was 
carried out as a loading control.  The numbers above the blots represent the lane numbers, 
while the numbers below the blots represent the densitometry signal of the bands.  
Student’s two-tailed t tests were performed to determine significant differences between 
samples (*, P < 0.05). 
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Fig. 5. Expression of hbz depresses p30II levels, and loss of p30II compensates for loss 
of hbz. (A) 293T cells were transfected with pMHp30IIHA1 (p30) and increasing amounts 
of either pHBZ2 (HBZ) or pmHBZ (mHBZ).  Total RNA was isolated 48h post-
transfection, and the p30 mRNA amplified by real-time RT-PCR. GAPDH was amplified 
as an internal control, and did not exhibit significant differences between samples. A 
representative experiment is shown from two experiments.  Student’s two-tailed t tests 
were performed to determine significant differences between samples (**, P < 0.01).  (B) 
293T cells were transfected with pMHp30IIHA1 (p30) and either pHBZ2 (HBZ) or 
pmHBZ (mHBZ).  Western blot analysis was carried out 48h post-transfection to 
measure levels of HBZ (Flag) and p30 (HA) protein.  Detection of actin was carried out 
as a loading control.  The numbers below the blots represent the densitometry signal of 
the bands.  (C and D) 293T cells were transfected with the pACH.HBZ-WT or 
pACH.HBZ-∆SA plasmids with or without the p30II mutation, WT∆p30 and ∆SA∆p30.  
At 48h post-transfection, Western blot analysis was carried out on the (C) lysates and (D) 
viral supernatant for levels of viral Gag (p19 and p24). *, indicates background bands.  
Detection of actin was carried out as a loading control. The numbers above the blots 
represent the lane numbers, while the numbers below the blots represent the densitometry 
signal of the bands. 
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Fig. 6. Model for effect of hbz on tax. Schematic representation of a possible mechanism 
for hbz’s control of tax: (1) hbz mRNA inhibits p30II mRNA, which (2) leads to a 
reduction in the amount of p30II protein.  Thus, less p30II is translocated to the nucleus, 
and as a result, (3) less tax mRNA is retained in the nucleus.  (4) This results in the 
synthesis of more Tax protein, leading to an increase in viral gene expression and virus 
production. 
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Human T-cell leukemia virus type 1 (HTLV-1) infection depends on several 
virus-cell interactions to promote a productive replication.  Viral tropism and gene 
expression are major determinants of the levels of virus replication.  Viral tropism refers 
to cell-type specific differences in levels of virus expression in culture or in vivo.  For 
most viruses, tropism is regulated at the level of cell entry or at the level of viral gene 
expression (Ashok and Atwood, 2006; Marshall and Major, 2010; Tan et al., 2007).  The 
first step in establishing an infection is viral entry.  For this to occur, the viral Env must 
bind to a cell surface receptor.  However, entry into a cell does not guarantee the 
completion of the replication cycle.  Numerous post-entry events and/or cellular factors 
can influence the outcome of an infection, and hence, tropism.  In the case of HTLV-1, it 
is thought that its in vivo infection is probably influenced by a number of post-entry 
blocks, due to the discrepancy between its in vivo and in vitro tropisms, rather than 
exclusively by its interaction with a receptor.  However, it is difficult to conclusively 
state what influences HTLV-1 infection, since its receptor is still unknown.  A number of 
factors have been implicated in enhancing its entry (Jain et al., 2009; Jin et al., 2009; 
Jones et al., 2005; Lambert et al., 2009; Manel et al., 2003), but none to the level that 
would be expected for a cellular receptor.  
Viral gene expression is an important factor in the outcome of an infection, since 
it influences the way a virus interacts with its host.  In addition to structural and 
enzymatic genes, the HTLV-1 genome encodes several regulatory genes, including Tax, 
Rex, p12I, p30II, p13II, and HBZ.  Of these, Tax is considered to be the most important 
since it is a potent trans-acting transcriptional factor (Boxus et al., 2008), required by the 
virus to transform cells (Akagi, Ono, and Shimotohno, 1995; Matsuoka and Jeang, 2007).  
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Rex is a positive regulator of infection, which is involved in the nuclear export of 
unspliced or singly spliced viral RNA (Heger et al., 1999).  The p12I protein has been 
implicated in viral replication and T-cell activation (Albrecht and Lairmore, 2002), while 
p30II has been shown to be a negative post-transcriptional regulator (Albrecht and 
Lairmore, 2002; Baydoun, Bellon, and Nicot, 2008).  The p13II protein has not been as 
well studied, but could possibly be involved in influencing the balance between viral 
latency and productive infection (Silic-Benussi et al., 2010). HBZ is a newly identified 
gene that has numerous possible functions.  In its protein form, it is thought to down-
regulate Tax-mediated viral transcription (Matsuoka and Green, 2009), while in its RNA 
form, it is thought to promote proliferation of T-cells (Arnold et al., 2008; Satou et al., 
2006).  Taken together, it is evident that HTLV-1 viral gene expression influences many 
aspects of its infection and/or replication. 
In an effort to better understand the processes that regulate HTLV-1 infection, we 
sought to identify the viral receptor by carrying out a retroviral cDNA library screen of a 
permissive cell-line.  Additionally, we investigated the role of the novel hbz gene in viral 
gene expression. 
 
VIRAL TROPISM 
 
Earlier studies aimed at receptor detection used numerous experimental 
approaches to do so.  Several groups identified factors based on their ability to either 
positively or negatively affect HTLV-1 Env-induced syncytia formation (Al-Fahim et al., 
1999; Daenke and Booth, 2000; Daenke, McCracken, and Booth, 1999; Hildreth, 1998; 
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Hildreth, Subramanium, and Hampton, 1997; Imai et al., 1992; Niyogi and Hildreth, 
2001; Pique et al., 2000; Sagara et al., 2001; Sagara et al., 1998; Uchiyama, Ishikawa, 
and Imura, 1996).  Factors such as tetraspanins, integrins, and lipid raft-associated 
proteins were implicated in this manner.  Several groups studied factors such as HSPGs 
and DC-SIGN, as they had previously been shown to bind viral envelopes of other 
viruses (Jones et al., 2005; Okuma et al., 2003; Pinon et al., 2003), or facilitate fusion of 
HTLV-1-infected T cells (Jain et al., 2009).  One group looked at the functional 
properties of the HTLV-1 Env itself, by performing peptide mapping experiments 
(Sagara et al., 1996).  GLUT-1 was investigated based on the observation that cultured 
cell lines transfected with the HTLV-1 receptor binding domain blocked acidification of 
the cell culture media (Manel et al., 2003).  NRP-1 was studied since it was shown to be a 
constituent of the immune synapse and have properties consistent with those for a HTLV-
1 receptor (Ghez et al., 2006).  Despite the plethora of information gained from these 
experiments, they were all similar in the fact that they investigated factors based on their 
ability to somehow influence viral entry. 
Our approach was designed to tackle the receptor issue in a different manner and 
in a broader sense.  We developed a retroviral cDNA library screen to detect proteins that 
could serve as a receptor or attachment factor for HTLV-1.  The screen was based on 
introducing cDNA from a highly permissive cell line, which should express any potential 
receptor/attachment factor, into a poorly susceptible cell line, infecting the resulting 
cDNA-expressing cells with HTLV-1 pseudotyped viral particles, selecting for cells that 
permitted infection, and isolating any cDNAs expressed in those cells.  We introduced a 
retroviral HeLa S3 cDNA library into murine NIH 3T3 cells, and isolated approximately 
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460 cDNAs.  Of these, 20 were prioritized based on the number of times they were 
isolated, whether they were membrane proteins, and whether they had been implicated as 
HIV-dependency factors (Brass et al., 2008; Konig et al., 2008; Zhou et al., 2008) (Table 
1). 
The implications of finding an entry mediator(s) for HTLV-1 are tremendous, 
since cell surface receptors have been shown to be major determinants of cell tropism and 
pathology.  First and foremost, a receptor determines the route of virus entry into the 
host.  This can reveal, for example, whether a viral particle enters a cell via endocytosis 
or whether a signaling pathway is activated, which allows for entry.  Furthermore, it 
reveals information about the tropism of a virus which, in the case of HTLV-1, could 
explain the discrepancy between its in vivo and in vitro tropisms.  The receptor can also 
determine the pattern of viral spread.  We know that HTLV-1 is most efficiently spread 
through cell-to-cell contacts in vivo (Igakura et al., 2003; Majorovits et al., 2008); finding 
the receptor could help better understand this process.  Furthermore, though a variety of 
hematopoietic cells can be infected by HTLV-1 in vivo, CD4+ T-cells seem to be the 
largest reservoirs for the virus.  If CD4+ T-cells express the receptor, and the receptor is 
involved in promoting cell-to-cell contacts between T-cells, then these cells would be 
efficient at promoting viral spread, which could explain the in vivo cell preference.  One 
of the more important implications of determining the receptor for HTLV-1 would be its 
ability to act as a drug target.  Drugs designed to inhibit the HTLV-1-receptor interaction 
at the point of virus entry or attachment would provide a way to prevent infection even 
before it gets started.  Additionally, determining the mode of viral entry and spread also 
opens these processes up as potential drug targets.   
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Table 1 List of prioritized receptor candidates  
 
Receptor Candidate 
 
MPa MH (#)b 
 
HDFc 
Guanine nucleotide-binding protein subunit beta-2-like 1 (GNB2L1)   (5)  
Peroxiredoxin-1 (PrdX1)   (10)  
Phosphatidylinositol glycan anchor biosynthesis, class T (PIGT)   (13)  
Killer cell lectin-like receptor subfamily K, member 1 (KLRK1)    
HLA-A, -B, and -C (Major Histocompatibility Complex I)    
HLA-DRB1 (Major Histocompatibility Complex II)    
Flotillin-1 (FLOT-1)   (2)  
CD68   (3)  
Solute carrier family 16, member 3 (SLC16A3)    
Solute carrier family 38, member 5 (SLC38A5)   (2)  
Ras-related protein Rab3D   (2)  
Ligatin (LGTN)    
Transmembrane BAX inhibitor motif containing 6 (TMBIM6)   (3)  
Transmembrane emp24 domain-containing protein 10 (TMED10)   (2)  
Transmembrane 4 L6 family member 1 (TM4SF1)    
Protease, serine 21 (PRSS21)    
Transmembrane and coiled-coil domain-containing 1 (TMCO1)   (3)  
Yip1 domain family member 3 (YIPF3)    
Ankyrin repeat domain protein 16 (ANKRD16)    
F-box/WD repeat containing protein 5 (FBXW5)   (2)  
a MP - membrane protein 
b MH (#) - multiple hit (number of hits) 
c HDF - HIV-dependency factors identified in Brass et al. (2008), König et al. (2008), and Zhou et 
al. (2008) 
 
 
 
 
 
 
 
 
 
 
 138 
Future directions 
  The 20 candidate factors need to be evaluated to determine if any function 
independently as a receptor/attachment factor for HTLV-1.  NIH 3T3 cells expressing 
these candidates should be generated and tested for entry using HTLV-1 Env 
pseudotyped particles.  Any candidate factors conferring entry should be further 
evaluated by fusion assays.  Previous studies have shown that immunoadhesions, fusions 
between a protein of interest and the Fc region of human IgG, between the HTLV-1 SU 
and Fc region of human IgG maintain the biochemical properties of SU, and are a useful 
and sensitive tool in evaluating receptor-Env interactions (Jassal, Pohler, and Brighty, 
2001).  Furthermore, it would be useful to determine if expression of the candidate factor 
in permissive cell lines is necessary for HTLV-1 Env infection.  Abrogation of expression 
of the candidate with short interfering RNAs (siRNAs) would help in answering this 
question.  Since GLUT-1, NRP-1, and HSPGs have been implicated in enhancing viral 
entry, it might be useful to determine if the candidate factor works cooperatively with one 
or more of these factors, to promote viral entry.   
One reason for the discrepancy with in vivo and in vitro tropisms could be that in 
vitro experiments use only the HTLV-1 Env to determine viral entry, while in vivo 
infections involve the entire virus.  This would suggest that the tropism of HTLV-1 is not 
determined solely by its Env-receptor interaction, but possibly at least partially by a post-
entry selection step.  To test the candidate factors against the entire virus, it would be 
useful to infect the NIH 3T3 cell-expressing candidates with viral particles generated 
using the cell-free infection assay developed by Derse et al. (2001).  This system 
generates virus stocks by transfecting cells with three plasmids: (i) a packaging plasmid 
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encoding HTLV-1 structural and regulatory proteins, (ii) an HTLV-1 transfer vector 
containing the firefly luciferase gene, and (iii) an envelope expression plasmid (Derse et 
al., 2001).  Single-round infections can be carried out and viral entry determined by the 
level of luciferase activity.  Testing the 20 candidate factors by these methods should 
narrow down the list and potentially identify a receptor/attachment factor candidate for 
HTLV-1. 
 
VIRAL GENE EXPRESSION 
 
The HTLV-1 bZIP gene, hbz, is alternatively spliced and has three isoforms, two 
of which are spliced, SP1 and SP2, and one which is unspliced, US.  The hbz SP1 and hbz 
US transcripts encode proteins, which share >95% homology.  The levels of hbz SP1 
transcript are four times more abundant than levels of the hbz US transcript in ATLL cells 
(Usui et al., 2008).  The hbz gene has dual functionality as the HBZ SP1 and HBZ US 
proteins are able to down-regulate Tax-mediated HTLV-1 transcription and Tax-
mediated cellular transcription (Matsuoka and Green, 2009), while the hbz SP1 mRNA 
has been shown to promote proliferation of T-cells (Arnold et al., 2008; Satou et al., 
2006).  In our efforts to better understand the role of hbz in HTLV-1 gene expression, we 
found a third function of hbz in which hbz mRNA promotes expression of tax mRNA, via 
down-regulation of p30II mRNA. 
We generated two RNA and two protein mutants of HBZ in the context of the 
ACH molecular clone.  We found that in the absence of hbz mRNA, the levels of tax 
mRNA were also significantly decreased.  This correlated to a decrease in the levels of 
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Tax protein, and to decreased levels of Tax activity.  Furthermore, when we added 
exogenous hbz, the levels of Tax activity increased.  Moreover, we noted that exogenous 
hbz only had an effect on Tax activity when Tax was expressed from the proviral clone, 
and not when Tax was expressed alone, without other viral proteins.  This suggested that 
the effect of hbz on tax was not direct, and that some other viral gene(s) was involved.  
Since hbz has (-) RNA polarity, we hypothesized that it could negatively regulate one of 
the (+) RNA viral products, which in turn would be a negative regulator of tax.  Hence, 
hbz could function as a repressor of a negative regulator of tax.  The p30II accessory 
protein is a negative regulator of tax, as it is able to bind tax mRNA and sequester it in 
the nucleus, preventing it from being exported into the cytoplasm and hence, being 
translated.  We tested the effect of hbz on p30II and found that it significantly decreased 
levels of p30II mRNA, in a dose dependent manner.  Furthermore, when we mutated the 
p30II protein in the context of the ACH molecular clone which was also defective in 
transcribing hbz mRNA, we found an increase in the levels of Tax activity.  Thus, we 
propose the following model (Fig. 1): hbz mRNA down-regulates p30II mRNA, which 
leads to a reduction in the levels of p30II protein.  As a result, less p30II protein is 
translocated to the nucleus.  This leads to less nuclear retention of tax mRNA, and hence, 
more export into the cytoplasm, where it is translated.  Since more Tax protein is 
translated, there is an increase in the levels of Tax-mediated functions. 
It seems likely that HTLV-1 would control its own gene expression.  Since Tax is 
highly immunogenic, the host mounts a strong cytotoxic T-lymphocyte (CTL) response 
against cells expressing Tax.  Hence, this may be a mechanism whereby the virus evades 
immune surveillance.  Most ATLL cells have been shown to have low to undetectable  
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Fig. 1. Model for effect of hbz on tax. Schematic representation of a possible 
mechanism for hbz’s control of tax: (1) hbz mRNA inhibits p30II mRNA, which (2) leads 
to a reduction in the amount of p30II protein.  Thus, less p30II is translocated to the 
nucleus, and as a result, (3) less tax mRNA is retained in the nucleus.  (4) This results in 
the synthesis of more Tax protein, leading to an increase in viral gene expression and 
virus production. 
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levels of Tax.  Though this phenomenon has been shown to be due to epigenetic changes 
of the 5′ LTR, it is possible that other mechanisms could exist, such as control of gene 
expression.  Recent studies have shown that p30II is a negative regulator of HTLV-1 
expression (Nicot et al., 2004), and that abrogation of p30II from a molecular clone in 
vivo led to lower proviral loads and decreased viral persistence (Silverman et al., 2004).  
Hence, it is possible that p30II is required by the virus to reduce levels of viral expression, 
and as a result, avoid immune recognition (Nicot et al., 2005).  Due to this, the virus may 
have developed an additional control, to ensure that levels of Tax were not reduced too 
much, or too early in infection, which would prevent T-cell transformation.  Since work 
in this dissertation has shown that hbz is able to promote tax expression by reducing the 
levels of p30II mRNA, it is possible that hbz and p30II work cooperatively to elegantly 
control the expression of Tax early in infection.    
 
Future directions 
Since hbz has been shown to down-regulate levels of p30II mRNA, it would be 
useful to determine the mechanism of this inhibition.  hbz is naturally an antisense RNA 
to genes on the positive strand of the genome, including p30II.  It has been evaluated for 
the possibility that it is processed into a microRNA (miRNA), but such a miRNA was not 
detected (Satou et al., 2006).  Nevertheless, it would be worthwhile to independently test 
for the presence of miRNAs.  It is possible that hbz and p30II mRNAs form a double 
stranded (ds)-RNA structure, which could get degraded by cellular host machinery.  
Since ds-RNA species are processed into small interfering RNAs (siRNAs) by the 
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cellular protein Dicer (He and Hannon, 2004), it would be interesting to see whether 
Dicer is capable of degrading any hbz/p30II ds-RNA species. 
HBZ transgenic mice have been generated by D. Rauch and J. Harding in the 
Ratner laboratory.  The HBZ transgene is under the control of the granzyme B promoter, 
which restricts HBZ expression to the mature natural killer (NK)/T-cell compartment.  
We have confirmed expression of HBZ from the transgene (Fig. 2).  The HBZ mice do 
not show gross abnormalities.  These mice need to be evaluated for the levels of hbz 
mRNA and HBZ protein in the different tissue compartments.  In addition, the levels of 
NK cells and CD4+ T-cells should be determined, as mice generated previously showed 
increased levels of CD4+ T-cells in the spleen, in the presence of hbz (though the 
transgene in these mice was under the control of the CD4 promoter) (Satou et al., 2006).  
The hbz transgenic mice have been bred with Tax transgenic mice, also under the control 
of the granzyme B promoter (Grossman et al., 1995).  These transgenic mice develop 
large granular lymphocytic leukemia.  It would be interesting to see what effect, if any, 
hbz has on the tumors present in the Tax mice.  Again, it would be necessary to evaluate 
the levels of both hbz and tax mRNA and protein in the different tissue compartments. 
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Fig. 2.  Expression of HBZ from HBZ transgene.  (A) Schematic representation of the 
transgene showing HBZ under the control of the granzyme B promoter. (B) 293T cells 
were transfected with the transgene and empty vector, and Western blot analysis with 
anti-HBZ antiserum and anti-actin carried out on the lysates 48 hours later.   
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CONCLUSIONS 
 
The goal of this dissertation was to better understand the regulation of HTLV-1 
infection and replication, as they relate to viral tropism and gene expression.  As a major 
determinant of viral tropism is envelope-receptor binding, we designed a retroviral cDNA 
library screen in an effort to identify the HTLV-1 receptor/attachment factor.  We have 
20 potential, high-priority candidates, which we are confident will get us closer to finding 
the HTLV-1 receptor.  In addition to being essential in regulating infection, viral gene 
expression is an important component of viral tropism.  In an effort to dissect the role of 
hbz in gene expression, we found that there is complex interplay of viral genes, which 
could be important in regulating the expression of Tax, and consequently, the emergence 
of disease.  The importance of a cellular receptor and viral genes that control Tax 
expression in regulating HTLV-1 infection and replication make them prime targets for 
the development of new therapeutics. 
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